EP1483295B1 - Anticorps rs7 - Google Patents

Anticorps rs7 Download PDF

Info

Publication number
EP1483295B1
EP1483295B1 EP03743420A EP03743420A EP1483295B1 EP 1483295 B1 EP1483295 B1 EP 1483295B1 EP 03743420 A EP03743420 A EP 03743420A EP 03743420 A EP03743420 A EP 03743420A EP 1483295 B1 EP1483295 B1 EP 1483295B1
Authority
EP
European Patent Office
Prior art keywords
antibody
fragment
fusion protein
mab
diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP03743420A
Other languages
German (de)
English (en)
Other versions
EP1483295A2 (fr
Inventor
Serengulam Govindan
Zhengxing Qu
Hans J. Hansen
David M. Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Priority to EP18211762.2A priority Critical patent/EP3483183B1/fr
Priority to EP08021299.6A priority patent/EP2287201B1/fr
Publication of EP1483295A2 publication Critical patent/EP1483295A2/fr
Application granted granted Critical
Publication of EP1483295B1 publication Critical patent/EP1483295B1/fr
Priority to CY20211100596T priority patent/CY1124289T1/el
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Definitions

  • the present invention is related to a humanized antibody which recognizes epithelial glycoprotein-1, and fragments thereof, a cancer cell targeting-diagnostic or therapeutic conjugate comprising an antibody component comprising such antibody or fragment, a multivalent, multispecific antibody comprising one or more of such antibody, an antibody fusion protein comprising such antibody, a DNA sequence comprising a nucleic acid encoding such antibody or fragment thereof, an expression vector comprising such DNA sequence, a host cell comprising such DNA sequence, the use of such antibody or fragment thereof, and an in vitro method of diagnosing a malignancy in a subject using such antibody or fragment thereof.
  • Man-made binding proteins in particular monoclonal antibodies and engineered antibodies or antibody fragments, have been tested widely and shown to be of value in detection and treatment of various human disorders, including cancers, autoimmune diseases, infectious diseases, inflammatory diseases, and cardiovascular diseases ( Filpula and McGuire, Exp. Opin. Ther. Patents (1999) 9: 231-245 ).
  • antibodies labeled with radioactive isotopes have been tested to visualize tumors after injection to a patient using detectors available in the art.
  • the clinical utility of an antibody or an antibody-derived agent is primarily dependent on its ability to bind to a specific targeted antigen.
  • Selectivity is valuable for delivering a diagnostic or therapeutic agent, such as isotopes, drugs, toxins, cytokines, hormones, growth factors, enzymes, conjugates, radionuclides, or metals, to a target location during the detection and treatment phases of a human disorder, particularly if the diagnostic or therapeutic agent is toxic to normal tissue in the body.
  • a diagnostic or therapeutic agent such as isotopes, drugs, toxins, cytokines, hormones, growth factors, enzymes, conjugates, radionuclides, or metals
  • the potential limitations of antibody systems are discussed in Goldenberg, The American Journal of Medicine (1993) 94: 298-299 .
  • the important parameters in the detection and treatment techniques are the amount of the injected dose specifically localized at the site(s) where target cells are present and the uptake ratio, i.e. the ratio of the concentration of specifically bound antibody to that of the radioactivity present in surrounding normal tissues.
  • the uptake ratio i.e. the ratio of the concentration of specifically bound antibody to that of the radioactivity present in surrounding normal tissues.
  • Target antigens both in tumor and other tissues
  • bone marrow toxicity resulting from the slow blood-clearance of the radiolabeled antibodies.
  • the amount of targeting antibodies accreted by the targeted tumor cells is influenced by the vascularization and barriers to antibody penetration of tumors, as well as intratumoral pressure.
  • Non-specific uptake by non-target organs such as the liver, kidneys or bone-marrow is another potential limitation of the technique, especially for radioimmunotherapy, where irradiation of the bone marrow often causes the dose-limiting toxicity.
  • direct targeting is a technique designed to target specific antigens with antibodies carrying diagnostic or therapeutic radioisotopes.
  • the direct targeting approach utilizes a radiolabeled anti-tumor monospecific antibody that recognizes the target tumor through its antigens.
  • the technique involves injecting the labeled monospecific antibody into the patient and allowing the antibody to localize at the target tumor to obtain diagnostic or therapeutic benefits. The unbound antibody clears the body. This approach can be used to diagnose or treat additional mammalian disorders.
  • AES Affinity Enhancement System
  • the AES utilizes a radiolabeled hapten and an anti-tumor/anti-hapten bispecific binding protein that recognizes both the target tumor and the radioactive hapten. Haptens with higher valency and binding proteins with higher specificity may also be utilized for this procedure.
  • the technique involves injecting the binding protein into the patient and allowing it to localize at the target tumor.
  • the radiolabeled hapten After a sufficient amount of time for the unbound binding protein to clear from the blood stream, the radiolabeled hapten is administered.
  • the hapten binds to the antibody-antigen complex located at the site of the target cell to obtain diagnostic or therapeutic benefits.
  • the unbound hapten clears the body.
  • Barbet mentions the possibility that a bivalent hapten may crosslink with a bispecific antibody, when the latter is bound to the tumor surface.
  • the radiolabeled complex is more stable and stays at the tumor for a longer period of time. This system can be used to diagnose or treat mammalian disorders.
  • Shih L B et al. ( Shih L B et al., Cancer Research, vol. 55, no. 23, Suppl, pages 5587S-5863S, 1 December 1995 ) describe an antibody which is not in the public domain and which is referred to as RS7.
  • This antibody is said to define an antigen which is present in tumors of the lung, stomach, bladder, breast, ovary, uterus and prostate, without disclosing the chemical nature of such antigen.
  • EGP-1 epithelial glycoprotein-1
  • TROP2 tumor-associated antigen
  • the present invention provides a humanized antibody or fragment thereof, wherein the complementarity determining regions (CDRs) of the light chain variable region of the antibody, or fragment thereof, comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT and wherein the CDRs of the heavy chain variable region of the antibody, or fragment thereof, comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of.
  • WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV, whereby such antibody, or fragment thereof, recognises epithelial glycoprotein-1.
  • the humanized antibody, or fragment thereof comprises the CDRs of a murine RS7 MAb and the framework region (FR) of the light and heavy chain variable regions of a human antibody, wherein the CDRs of the light chain variable region of the antibody, or fragment thereof, comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT; and the CDRs of the heavy chain variable region of the antibody, or fragment thereof, comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV. Still preferred, the humanized antibody or fragment thereof further comprises the FRs of the light and heavy chain constant regions of a human antibody.
  • the antibody or antibody fragment of the present invention binds the same epitope as the murine RS7 antibody disclosed by Stein ( infra ) and other earlier studies.
  • the antibody or fragment may bind an epitope distinct from the epitope that the murine RS7 antibody disclosed by Stein binds.
  • the anti- EGP-1, or anti-TROP2 antibody or fragment thereof is a humanized RS7 antibody or fragment thereof.
  • the humanized RS7 antibody or fragment comprises a FR of a light and/or heavy chain that comprises at least one amino acid substituted by an amino acid residue found at a corresponding location in the RS7 murine antibody.
  • at least one of the substituted amino acids is preferably at a location selected from the group consisting of residue 38, 46, 68 and 91 of the murine heavy chain variable region of figure 3B
  • at least one of the substituted amino acids is preferably at a location selected from the group consisting of residue 20, 85 and 100 of the murine light chain variable region of figure 3A .
  • an antibody fusion protein that comprises at least two anti-EGP-1 MAbs or fragments thereof, wherein the MAbs or fragments thereof are selected from the anti-EGP-1 MAbs or fragments thereof of the present invention.
  • the antibody fusion protein comprises at least one first anti-EGP-1 MAb or fragment thereof of any of the anti-EGP-1 antibodies of the present invention and at least one second MAb or fragment thereof, other than the anti-EGP antibodies or fragment thereof in the present invention.
  • the second antibody or fragment thereof may be a carcinoma-associated antibody or fragment thereof.
  • Another preferred embodiment is a fusion protein that comprises two different epitope-binding anti-EGP-1 antibodies or fragments thereof.
  • the latter binding protein is useful for pretargeting a target antigen.
  • a method of delivering a diagnostic agent, a therapeutic agent, or a combination thereof to a target comprising: (i) administering to a subject a multivalent, multispecific MAb, (ii) waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and (iii) administering to said subject a carrier molecule comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to a binding site of said antibody, is also described, whereby such multivalent, multispecific MAb comprises one or more antibodies according to the present invention.
  • the antibodies and fragments according to the present invention can be used in a method of delivering a diagnostic or therapeutic agent to a targeted disease that expresses EGP-1 antigen.
  • a method of delivering a diagnostic or therapeutic agent, or a combination thereof, to a target comprising (i) providing a composition that comprises an anti-EGP-1 antibody or fragment thereof according to the present invention bound to at least one thereapeutic and/or diagnostic agent and (ii) administering to a subject in need thereof said composition, is described.
  • the diagnostic or therapeutic agent is selected from the group consisting of an isotope, drug, toxin, imuno, modulator, hormone, enzyme, growth factor, radionuclide, metal, contrast agent, and detecting agent.
  • a method for delivering a diagnostic agent , a therapeutic agent, or a combination thereof to a target comprises (i) administering to a subject a multivalent, multispecific antibody according to the present invention comprising one or more antigen-binding sites having affinity toward an EGP-1 target antigen and one or more hapten bidning sites having an affinity toward a hapten molecule, (ii) waiting a sufficient amount of time for an amount of the non-binding antibody or fragment to clear a subject's blood stream, and (iii) administering to said subject a hapten comprising a diagnostic agent, a therapeutic agent, or a combination thereof.
  • Another object of the present invention to provide a cancer cell targeting diagnostic or therapeutic conjugate that comprises an anti-EGP-1 MAb or fragment thereof or an antibody fusion protein of any one of antibodies of the present invention and wherein the anti-EGP-1antibody or fragment thereof is bound to at least one diagnostic or therapeutic agent.
  • a suitable therapeutic agent is a drug that possesses the pharmaceutical property selected from the group consisting of an antimitotic, alkylating, antimetabolite, antiangiogenic, apoptotic, alkyloid antibiotic, and combinations thereof.
  • a therapeutic agent selected from the group consisting of a ntirogen mustard, ethylenimine derivative, alkyl sulfonate, nitrosurea, traizene, folic acid analog, antracycline, taxane, COX-2 inhibitor, tyrosine kinase inhibitor, pyrimidine analog, purine analog, antibiotic, enzyme, epipodophyllotoxin, platinim coordination complex, vinca alkaloid, substituted urea, methyl hydrazine derivative, adrenocorticol suppressant, antagonist, endostatin taxol, camptothecins, doxorubicin, doxorubicin analog, and a combination thereof.
  • the diagnostic agent is selected from the group consisting of a photoactive radionuclide, preferaby between 25 and 4000 keV, and a contrast agent.
  • a DNA sequence comprising a nucleic acid encoding a MAb or fragment that contains a anti-EGP-1 MAb or fragment thereof of the present invention; an antibody fusion protein containing at least two of said MAbs or fragments thereof; an antibody fusion protein or fragment thereof containing, at least one first anti-EGP-1 MAb or fragment thereof containing the MAb or fragment thereof of the anti-EGP-1 antibodies and fragments of the present invention and at least one second MAb or fragment thereof, other than the anti-EGP-1 MAb or fragment thereof described herein; or an antibody fusion protein comprising at least one first MAb or fragment thereof comprising said MAb or fragment thereof of any of the antibodies described herein and at least one second MAb or fragment thereof, other than the MAb or fragment thereof of any one of the antibodies described herein, wherein the second MAb is reactive with an antigen selected from the group consisting of EGP-2, MUC 1-4, A33, CSAp, CEA, Le(y),Tn,Tag-72, PSMA
  • the second MAb may instead be reactive with vascular endothelial antigens associated with tumors, such as VEGF (vascular endothelial growth factor) and P1GF (placenta growth factor). Selection of the second antibody is dependent on tumor cell type.
  • anti-PSMA or anti-PSA antibodies may be used for treating or diagnosing prostate cancer, anti-CEA or anti-MUC1, MUC2, MUC3 and MUC4 antibodies for breast, ovarian, lung, and colon cancer, EGFR for colon and head and neck cancers, anti-CSAp antibodies for colon and ovarian cancer, and anti-HER/neu for breast, ovarian and other cancers. These are merely given as examples, and are not intended to be limiting. Expression vectors and host cells containing this DNA sequence are also preferred embodiments of the present invention.
  • a method for diagnosing or treating cancer comprises (i) administering to a subject in need thereof amultivalent, multispecific antibody according to the present invention comprising one or more antigen-binding sites having affinity toward an EGP-1 horrt antigen and one or more hapten bidning sites having an affinity toward a hapten molecule; (ii) waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and (iii) administering to said subject a hapten comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to a binding site of said antibody.
  • the methods for diagnosing and treating a malignancy may comprise administering a therapeutically effective amount of an anti-EGP-1 fusion protein or fragment thereof or a therapeutic conjugate comprising a EGP-1 MAb or fragment thereof according to the present invention, wherein the EGP-1 MAb or fragment thereof or antibody fusion protein is bound to at least one therapeutic agent in a pharmaceutically suitable excipient.
  • naked and-EGP-1 antibodies and fragments thereof, including naked anti-EGP-1 fusion proteins and fragments thereof can also be used for treating a malignancy.
  • Naked anti-EGP-1 antibodies may be used for in vitro diagnosis of a malignancy, for example with immunoassays or immunohistochemistry, but not for in vivo diagnosis, unless this involves a pretargeting technology, such as AES.
  • Labeled EGP-1 antibodies may be used for in vivo diagnosis and treatment of a malignancy.
  • described herein is a method of treating a cancer cell in a subject comprising (i) administering to a subject a therapeutically effective amount of a composition containing an anti-EGP-1 MAb or fragment thereof or an antibody fusion protein according to the present invention (ii) formulating the EGP-1 MAb or fragment thereof or antibody fusion protein in a pharmaceutically suitable excipient.
  • combinations of naked MAbs and fragments thereof with conjugated MAbs or fragments thereof or fusion proteins or fragments thereof for diagnosis and treatment are also contemplated in the instant invention.
  • An RS7 antibody (previously designated RS7-3G11) is a murine IgG 1 raised against a crude membrane preparation of a human primary squamous cell carcinoma from the lung. See Stein et al., Cancer Res. 50: 1330 (1990 ), which is fully incorporated by reference. The RS7 antibody recognizes a tumor-associated antigen, which was defined by the murine MAb RS7-3G11 raised against human non-small-cell lung carcinoma. Stein et al. discloses that the RS7 antibody recognizes a 46-48 kDa glycoprotein, characterized as cluster 13. Stein et al., Int. J. Cancer Supp. 8:98-102 (1994 ). See also, Basu et al., Int. J.
  • EGP- 1 epidermal glycoprotein-1
  • RS7 MAb detects antigen on a variety of tumor types, with limited binding to normal human tissue.
  • the RS7 antibody is reactive with an EGP-1 glycoprotein, which can be rapidly internalized. EGP-1 is expressed primarily by carcinomas such as carcinomas of the lung, stomach, urinary bladder, breast, ovary, uterus, and prostate.
  • Localization and therapy studies using radiolabeled murine RS7 MAb in animal models have demonstrated tumor targeting and therapeutic efficacy (Stein et al., (1990), supra Stein et al., (1991). supra ) .
  • the RS7 MAb is rapidly internalized into target cells ( Stein et al. (1993), supra ).
  • the internalization rate constant for RS7 MAb is intermediate between the internalization rate constants of two other rapidly internalizing MAbs which have been demonstrated to be useful for immunotoxin production. Id. It is well-documented that the internalization of immunotoxin conjugates is an absolute requirement for anti-tumor activity. ( Pastan et al., Cell 47:641 (1986 )). Internalization of drug immunoconjugates also has been described as a major factor in anti-tumor efficacy. ( Yang et al., Proc. Nat'1 Acad Sci. USA 85: 1189 (1988 )). Therefore, the RS7 antigen may be an important target for those types of immunotherapy that require internalization of the therapeutic agent.
  • the antibody exhibits several important properties, which make it a candidate for clinical diagnostic and therapeutic applications. Since the RS7 antigen provides a useful target for diagnosis and therapy, it is desirable to obtain a MAb that recognizes an epitope of the RS7 antigen. Moreover, the availability of chimeric, humanized and human RS7 antibodies is essential for the development of a double-determinant enzyme-linked immunosorbent assay (ELISA), which is desireable for detecting the RS7 antigen in clinical samples, and essential for in vivo applications in humans.
  • ELISA enzyme-linked immunosorbent assay
  • the present invention describes humanized antibodies and fragments thereof that bind the RS7 antigen and can be used for diagnostic and therapeutic methods.
  • Humanized antibodies and antibody fragments are described in Provisional U.S. Application titled “Anti-CD20 Antibodies And Fusion Proteins Thereof And Methods Of Use", Attorney Docket No. 18733/1073, U.S. Provisional No. 60/356,132 , U.S. Provisional Application No. 60/416,232 and Attorney Docket No. 18733/1155; hMN-14 antibodies, such as those disclosed in U.S. Application No. 5,874,540 , which is a Class III anti-carcinoembryonic antigen antibody (anti-CEA antibody); Mu-9antibodies, such as those described in U.S.
  • a humanized antibody is a recombinant protein in which the CDRs from an antibody of one species, e.g., a rodent antibody, are transferred from the heavy and variable chains of the rodent antibody into human heavy and light variable domains.
  • the RS7 antibody is humanized. Because non-human monoclonal antibodies can be recognized by the human host as a foreign protein, and repeated injections can lead to harmful hypersensitivity reactions, humanization of a murine RS7 sequences can reduce the adverse immune response that patients may experience. For murine-based monoclonal antibodies this is often referred to as a Human Anti-Mouse Antibody (HAMA) response.
  • HAMA Human Anti-Mouse Antibody
  • the antibody is an anti-EGP-1 antibody or fragment thereof that is a humanized anti-EGP-1 antibody. Preferably some human residues in the framework regions of the humanized RS7 antibody or fragments thereof are replaced by their murine counterparts. It is also preferred that a combination of framework sequences from 2 different human antibodies are used for V H .
  • the constant domains of the antibody molecule are derived from those of a human antibody.
  • the antibody and fragments thereof of the present invention is preferably raised against a crude membrane preparation from a human primary squamous cell carcinoma of the lung.
  • the RS7 antibody and fragments thereof is raised against a membrane preparation of viable cells from a human ovarian carcinoma cell line.
  • the RS7 antigen is provided by viable Colo 316 cells.
  • the RS7 antibody can be obtained using a substantially pure preparation of the RS7 antigen.
  • a substantially pure protein is a protein that is essentially free from contaminating cellular components, which are associated with the protein in nature.
  • the term "RS7 antibody” includes humanized RS7 antibodies.
  • Monoclonal antibodies to specific antigens may be obtained by methods known to those skilled in the art. See, for example, Kohler and Milstein, Nature 256: 495 (1975 ), and Coligan et al. (eds.), CURRENT PROTOCOLS IN IMMUNOLOGY, VOL. 1, pages 2.5.1-2.6.7 (John Wiley & Sons 1991 ) (hereinafter "Coligan").
  • RS7 antigen MAbs such as RS7
  • RS7 antigen MAbs can be obtained by injecting mice with a composition comprising the RS7 antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B-lymphocytes, fusing the B-lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones which produce antibodies to RS7 antigen, culturing the clones that produce antibodies to RS7 antigen, and isolating RS7 antibodies from the hybridoma cultures.
  • the antibodies can be sequenced and subsequently prepared by recombinant techniques.
  • Humanization of murine antibodies and antibody fragments is well known to those skilled in the art.
  • humanized monoclonal antibodies are produced by transferring mouse complementary determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then, substituting human residues in the framework regions of the murine counterparts.
  • the use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions.
  • a human antibody i.e., human EGP-1 MAbs or other human antibodies, such as anti-EGP-2, MUC1-4, CEA, CC49, CSAp, PSMA, PSA, EGFR, A33 and HER2/neu MAbs for combination therapy with humanized, RS7 antibodies can be obtained from a transgenic non-human animal. See, e.g., Mendez et al., Nature Genetics, 15: 146-156 (1997 ); U.S. Patent No. 5,633,425 .
  • a human antibody that can be used for combination therapy may also be reactive with an antigen selected from the group consisting of Le(y),Tn, Tag-72, AFP, HCG, HCG-beta, ferritin, PAP, EGP-2, histone, cytokeratin, Tenascin, CanAg, kidney cancer G 250, VGFR1, VGFR2, or a combination thereof.
  • an antigen selected from the group consisting of Le(y),Tn, Tag-72, AFP, HCG, HCG-beta, ferritin, PAP, EGP-2, histone, cytokeratin, Tenascin, CanAg, kidney cancer G 250, VGFR1, VGFR2, or a combination thereof.
  • a human antibody can be recovered from a transgenic mouse possessing human immunoglobulin loci.
  • the mouse humoral immune system is humanized by inactivating the endogenous immunoglobulin genes and introducing human immunoglobulin loci.
  • the human immunoglobulin loci are
  • YACs yeast artificial chromosomes
  • each insert is approximately 1 Mb in size
  • YAC construction requires homologous recombination of overlapping fragments of the immunoglobulin loci.
  • the two YACs, one containing the heavy-chain loci and one containing the light-chain loci, are introduced separately into mice via fusion of YAC-containing yeast spheroblasts with mouse embryonic stem cells.
  • Embryonic stem cell clones are then microinjected into mouse blastocysts. Resulting chimeric males are screened for their ability to transmit the YAC through their germline and are bred with mice deficient in murine antibody production. Breeding the two transgenic strains, one containing the human heavy-chain loci and the other containing the human light-chain, loci, creates progeny which produce human antibodies in response to immunization.
  • V ⁇ (variable light chain) and V H (variable heavy chain) sequences for RS7 antibodies can be obtained by a variety of molecular cloning procedures, such as RT-PCR, 5'-RACE, and cDNA library screening.
  • VH and V ⁇ genes of the MAb RS7 were cloned by PCR amplification from the hybridoma cells by RT-PCR and 5' RACE, respectively, and their sequences determined by DNA sequencing.
  • the cloned V L and V H genes can be expressed in cell culture as a chimeric Ab as described by Orlandi et al., (Proc. Natl. Acad Sci., USA, 86: 3833 (1989 )).
  • a humanized RS7 antibody can then be designed and constructed as described by Leung et al. (Mol. Immunol. 32: 1413 (1995 )).
  • cDNA can be prepared from any known hybridoma line or transfected cell line producing a murine or chimeric RS7 antibody by general molecular cloning techniques ( Sambrook et al., Molecular Cloning, A laboratory manual, 2nd Ed (1989 )). In a preferred embodiment, the RS7 hybridoma line is used.
  • V ⁇ sequence for the mAb may be amplified using the primers VK1BACK and VK1FOR (Orlandi et al, 1989) or the extended primer set described by Leung et al. (BioTechniques, 15: 286 (1993 )), while V H sequences can be amplified using the primer pair VH1BACK/VH1FOR (Orlandi et al. , 1989 above), or the primers annealing to the constant region of murine IgG described by Leung et al. (Hybridoma, 13:469 (1994)).
  • V ⁇ and VH fragments can be purified on 2% agarose (BioRad, Richmond, CA).
  • the humanized V genes can be constructed by a combination of long oligonucleotide template syntheses and PCR amplification as described by Leung et al. (Mol. Immunol., 32: 1413 (1995 )).
  • PCR products for V ⁇ can be subcloned into a staging vector, such as a pBR327-based staging vector, VKpBR, that contains an Ig promoter, a signal peptide sequence and convenient restriction sites to facilitate in-frame ligation of the V ⁇ PCR products.
  • PCR products for V H can be subcloned into a similar staging vector, such as the pBluescript-based VHpBS. Individual clones containing the respective PCR products may be sequenced by, for example, the method of Sanger et al. (Proc. Natl. Acad. Sci., USA, 74: 5463 (1977 )).
  • DNA sequences described herein are to be taken as including all alleles, mutants and variants thereof, whether occurring naturally or induced.
  • V ⁇ and VH The expression cassettes containing the V ⁇ and VH, together with the promoter and signal peptide sequences can be excised from VKpBR and VHpBS, respectively, by double restriction digestion as HindIII-BamHI fragments.
  • the V ⁇ and VH expression cassettes can then be ligated into appropriate expression vectors, such as pKh and pG1g, respectively ( Leung et al., Hybridoma, 13:469 (1994 )).
  • the expression vectors can be co-transfected into an appropriate cell, e.g., myeloma Sp2/0-Ag14 (ATCC, VA), colonies selected for hygromycin resistance, and supernatant fluids monitored for production of a chimeric or humanized RS7 MAb by, for example, an ELISA assay, as described below.
  • the V ⁇ and VH expression cassettes can be assembled in the modified staging vectors, VKpBR2 and VHpBS2, excised as XbaI/BamHI and NhoI/BamHI fragments, respectively, and subcloned into a single expression vector, such as pdHL2, as described by Gilles et al. (J. Immunol.
  • Co-transfection and assay for antibody secreting clones by ELISA can be carried out as follows. About 10 ⁇ g of VKpKh (light chain expression vector) and 20 ⁇ g of VHpG1g (heavy chain expression vector) can be used for the transfection of 5 X 10 6 SP2/0 myeloma cells by electroporation (BioRad, Richmond, CA) according to Co et al., J. Immunol., 148:1149 (1992 ). Following transfection, cells may be grown in 96-well microtiter plates in complete HSFM medium (Life Technologies, Inc., Grand Island, NY) at 37°C, 5%CO 2 .
  • complete HSFM medium Life Technologies, Inc., Grand Island, NY
  • the selection process can be initiated after two days by the addition of hygromycin selection medium (Calbiochem, San Diego, CA) at a final concentration of 500 units/ml of hygromycin. Colonies typically emerge 2-3 weeks post-electroporation. The cultures can then be expanded for further analysis.
  • hygromycin selection medium Calbiochem, San Diego, CA
  • Suitable host cells include microbial or mammalian host cells.
  • a preferred host is the human cell line, PER.C6, which was developed for production of MAbs, and other fusion proteins.
  • a preferred embodiment of the present invention is a host cell comprising a DNA sequence encoding and anti-EGP-1 MAb, conjugate, fusion protein or fragments thereof.
  • PER.C6 cells ( WO 97/00326 ) were generated by transfection of primary human embryonic retina cells, using a plasmid that contained the Adserotype 5 (Ad5) ElA- and ElB-coding sequences (Ad5 nucleotides 459-3510) under the control of the human phosphoglycerate kinase (PGK) promoter.
  • Ad5 Adserotype 5
  • ElA- and ElB-coding sequences Ad5 nucleotides 459-3510
  • E1A and E1B are adenovirus early gene activation protein 1A and 1B, respectively.
  • the methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, e.g. by glycosylation.
  • PER.C6 particularly useful as a host for recombinant protein production, such as PER.C6 is a fully characterized human cell line and it was developed in compliance with good laboratory practices.
  • PER.C6 can be grown as a suspension culture in defined serum-free medium devoid of any human- or animal-derived proteins and its growth is compatible with roller bottles, shaker flasks, spinner flasks and bioreactors with doubling times of about 35 hrs.
  • the presence of E1A causes an up regulation of expression of genes that are under the control of the CMV enhancer /promoter and the presence of E13 prevents p53-dependent apoptosis possibly enhanced through over expression of the recombinant transgene.
  • the cell is capable of producing 2 to 200-fold more recombinant protein and/or proteinaceous substance than conventional mammalian cell lines.
  • Transfectoma clones that are positive for the secretion of chimeric or humanized heavy chain can be identified by ELISA assay. Briefly, supernatant samples ( ⁇ 100 ⁇ l) from transfectoma cultures are added in triplicate to ELISA microtiter plates precoated with goat anti-human (GAH)-IgG, F(ab') 2 fragment-specific antibody (Jackson ImmunoResearch, West Grove, PA). Plates are incubated for 1 h at room temperature. Unbound proteins are removed by washing three times with wash buffer (PBS containing 0.05% polysorbate 20).
  • wash buffer PBS containing 0.05% polysorbate 20
  • HRP horseradish peroxidase conjugated GAH-IgG, Fc fragment-specific antibodies
  • Jackson ImmunoResearch is added to the wells, (100 ⁇ l of antibody stock diluted x 10 4 , supplemented with the unconjugated antibody to a final concentration of 1.0 ⁇ g/ml).
  • a reaction solution [100 ⁇ l, containing 167 ⁇ g of orthophenylene-diamine (OPD) (Sigma, St. Louis, MO), 0.025% hydrogen peroxide in PBS], is added to the wells. Color is allowed to develop in the dark for 30 minutes.
  • OPD orthophenylene-diamine
  • reaction is stopped by the addition of 50 ⁇ l of 4 N HCl solution into each well before measuring absorbance at 490 nm in an automated ELISA reader (Bio-Tek instruments, Winooski, VT). Bound chimeric antibodies are than determined relative to an irrelevant chimeric antibody standard (obtainable from Scotgen, Ltd., Edinburg, Scotland).
  • Antibodies can be isolated from cell culture media as follows. Transfectoma cultures are adapted to serum-free medium. For production of chimeric antibody, cells are grown as a 500 ml culture in roller bottles using HSFM. Cultures are centrifuged and the supernatant filtered through a 0.2 ⁇ membrane. The filtered medium is passed through a protein A column (1 x 3 cm) at a flow rate of 1 ml/min. The resin is then washed with about 10 column volumes of PBS and protein A-bound antibody is eluted from the column with 0.1 M glycine buffer (pH 3.5) containing 10 mM EDTA.
  • 0.1 M glycine buffer pH 3.5
  • Fractions of 1.0 ml are collected in tubes containing 10 ⁇ l of 3 M Tris (pH 8.6), and protein concentrations determined from the absorbance at 280/260 nm. Peak fractions are pooled, dialyzed against PBS, and the antibody concentrated, for example, with the Centricon 30 (Amicon, Beverly, MA). The antibody concentration is determined by ELISA, as before, and its concentration adjusted to about 1 mg/ml using PBS. Sodium azide, 0.01 % (w/v), is conveniently added to the sample as preservative.
  • a humanized RS7 antibody or antibody fragment comprises the complementarity-determining regions (CDRs) of a murine RS7 MAb and the framework (FR) regions of the light and heavy chain variable regions of a human antibody and the light and heavy chain constant regions of a human antibody, wherein the CDRs of the light chain variable region of the humanized RS7 comprises CDR1 comprising an amino acid sequence of KASQDVSIAVA; CDR2 comprising an amino acid sequence of SASYRYT; and CDR3 comprising an amino acid sequence of QQHYITPLT; and the CDRs of the heavy chain variable region of the humanized RS7 MAb comprises CDR1 comprising an amino acid sequence of NYGMN; CDR2 comprising an amino acid sequence of WINTYTGEPTYTDDFKG and CDR3 comprising an amino acid sequence of GGFGSSYWYFDV.
  • RS7 MAbs can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, for example, Coligan at pages 2.7.1-2.7.12 and pages 2.9.1-2.9.3. Also, see Baines et al., "Purification of Immunoglobulin G (IgG)," in METHODS IN MOLECULAR BIOLOGY, VOL. 10, pages 79-104 (The Humana Press, Inc. 1992 ).
  • RS7 MAbs can be characterized by a variety of techniques that are well-known to those of skill in the art. For example, the ability of an RS7 MAb to bind to the RS7 antigen can be verified using an indirect immunofluorescence assay, flow cytometry analysis, or Western analysis.
  • the present invention contemplates the use of fragments of RS7 and hRS7 antibodies.
  • Antibody fragments which recognize specific epitopes can be generated by known techniques.
  • the antibody fragments are antigen binding portions of an antibody, such as F(ab') 2 , Fab', Fab, Fv, sFv and the like.
  • Other antibody fragments include, but are not limited to: the F(ab)' 2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab' fragments, which can be generated by reducing disulfide bridges of the F(ab)' 2 fragments. These methods are described, for example, by Goldenberg, U.S. patent Nos. 4,036,945 and 4,331,647 and references contained therein.
  • Fab' expression libraries can be constructed ( Huse et al., 1989, Science, 246:1274-1281 ) to allow rapid and easy identification of monoclonal Fab' fragments with the desired specificity.
  • the present invention encompasses antibodies and antibody fragments.
  • a single chain Fv molecule comprises a VL domain and a VH domain.
  • the VL and VH domains associate to form a target binding site. These two domains are further covalently linked by a peptide linker (L).
  • L peptide linker
  • a scFv molecule is denoted as either VL-L-VH if the VL domain is the N-terminal part of the scFv molecule, or as VH-L-VL if the VH domain is the N-terminal part of the scFv molecule.
  • An antibody fragment can be prepared by proteolytic hydrolysis of the full length antibody or by expression in E . coli or another host of the DNA coding for the fragment.
  • An antibody fragment can be obtained by pepsin or papain digestion of full length antibodies by conventional methods.
  • an antibody fragment can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted F(ab') 2 .
  • This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulfhydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments.
  • a CDR is a segment of the variable region of an antibody that is complementary in structure to the epitope to which the antibody binds and is more variable than the rest of the variable region. Accordingly, a CDR is sometimes referred to as hypervariable region.
  • a variable region comprises three CDRs.
  • CDR peptides can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells.
  • cleaving antibodies such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical or genetic techniques may also be used, so long as the fragments, bind to the antigen that is recognized by the intact antibody.
  • Antibody fusion proteins can be prepared by a variety of conventional procedures, ranging from glutaraldehyde linkage to more specific linkages between functional groups.
  • the antibodies and/or antibody fragments are preferably covalently bound to one another, directly or through a linker moiety, through one or more functional groups on the antibody or fragment, e.g., amine, carboxyl, phenyl, thiol, or hydroxyl groups.
  • Various conventional linkers in addition to glutaraldehyde can be used, e.g., disiocyanates, diiosothiocyanates, bis(hydroxysuccinimide) esters, carbodiimides, maleimidehydroxysuccinimide esters, and the like.
  • a simple method to produce chimeric, humanized and human RS7 antibody fusion proteins is to mix the antibodies or fragments in the presence of glutaraldehyde to form an antibody fusion protein.
  • the initial Schiff base linkages can be stabilized, e.g., by borohydride reduction to secondary amines.
  • a diiosothiocyanate or carbodiimide can be used in place of glutaraldehyde as a non-site-specific linker.
  • Antibody fusion proteins are expected to have a greater binding specificity than MAbs, since the fusion proteins comprise moieties that bind to at least two epitopes of the RS7 antigen. Thus, antibody fusion proteins are the preferred form of RS7 antigen binding protein for therapy.
  • an antibody fusion protein comprises at least two chimeric, humanized or human RS7 MAbs, or fragments thereof, wherein at least two of the MAbs or fragments bind to different epitopes of the RS7 antigen or against an RS7 epitope and that of a totally different antigen.
  • a bispecific RS7 antibody fusion protein may comprise a CEA antibody or fragment thereof and the RS7 MAb or fragment thereof.
  • Such a bispecific RS7 antibody fusion protein can be prepared, for example, by obtaining an F(ab') 2 fragment from CEA as described above.
  • the interchain disulfide bridges of the antibody F(ab') 2 fragment are gently reduced with cysteine, taking care to avoid light-heavy chain linkage, to form Fab'-SH fragments.
  • the SH group(s) is (are) activated with an excess of bis-maleimide linker (1,1'-(methylenedi-4, 1-phenylene)bis-malemide).
  • the RS7 MAb is converted to Fab'-SH and then reacted with the activated CEA Fab'-SH fragment to obtain a bispecific RS7 antibody fusion protein.
  • a polyspecific RS7 antibody fusion protein can be obtained by adding RS7 antigen binding moieties to a bispecific, humanized or human RS7 antibody fusion protein.
  • a bispecific antibody fusion protein can be reacted with 2-iminothiolane to introduce one or more sulfhydryl groups for use in coupling the bispecific fusion protein to a third RS7 antigen MAb or fragment, using the bis-maleimide activation procedure described above.
  • Bispecific antibodies can be made by a variety of conventional methods, e.g., disulfide cleavage and reformation of mixtures of whole IgG or, preferably F(ab') 2 fragments, fusions of more than one hybridoma to form polyomas that produce antibodies having more than one specificity, and by genetic engineering.
  • Bispecific antibody fusion proteins have been prepared by oxidative cleavage of Fab' fragments resulting from reductive cleavage of different antibodies.
  • More selective linkage can be achieved by using a heterobifunctional linker such as maleimidehydroxysuccinimide ester. Reaction of the ester with an antibody or fragment will derivatize amine groups on the antibody or fragment, and the derivative can then be reacted with, e.g., and antibody Fab fragment having free sulfhydryl groups (or, a larger fragment or intact antibody with sulfhydryl groups appended thereto by, e.g., Traut's Reagent). Such a linker is less likely to crosslink groups in the same antibody and improves the selectivity of the linkage.
  • a heterobifunctional linker such as maleimidehydroxysuccinimide ester. Reaction of the ester with an antibody or fragment will derivatize amine groups on the antibody or fragment, and the derivative can then be reacted with, e.g., and antibody Fab fragment having free sulfhydryl groups (or, a larger fragment or intact antibody with sulfhydryl
  • ScFvs with linkers greater than 12 amino acid residues in length allow interacting between the V H and V L domains on the same chain and generally form a mixture of monomers, dimers (termed diabodies) and small amounts of higher mass multimers, ( Kortt et al., Eur. J. Biochem. (1994) 221: 151-157 ).
  • ScFvs with linkers of 5 or less amino acid residues prohibit intramolecular pairing of the V H and V L domains on the same chain, forcing pairing with V H and V L domains on a different chain.
  • Linkers between 3- and 12-residues form predominantly dimers ( Atwell et al., Protein Engineering (1999) 12: 597-604 ). With linkers between 0 and 2 residues, trimeric (termed triabodies), tetrameric (termed tetrabodies) or higher oligomeric structures of scFvs are formed; however, the exact patterns of oligomerization appear to depend on the composition as well as the orientation of the V-domains, in addition to the linker length.
  • scFvs of the anti-neuraminidase antibody NC10 formed predominantly trimers (V H to V L orientation) or tetramers (V L to V H orientation) with 0-residue linkers ( Dolezal et al., Protein Engineering (2000) 13: 565-574 ).
  • V H to V L orientation formed predominantly diabodies ( Atwell et al., Protein Engineering (1999) 12: 597-604 ); in contrast, the V L to V H orientation formed a mixture of tetramers, trimers, dimers, and higher mass multimers ( Dolezal et al., Protein Engineering (2000) 13: 565-574 ).
  • the 0-residue linker formed exclusively trimers and the 1-residue linker formed exclusively tetramers ( Le Gall et al., FEBS Letters (1999) 453: 164-168 ).
  • the RS7 antibodies and fragments thereof of the present invention can also be used to produce antigen-specific diabodies, triabodies and tetrabodies, which are multivalent but monospecific.
  • the non-covalent association of two or more scFv molecules can form functional diabodies, triabodies and tetrabodies.
  • Monospecific diabodies are homodimers of the same scFv, where each scFv comprises the V H domain from the selected antibody connected by a short linker to the V L domain of the same antibody.
  • a diabody is a bivalent dimer formed by the non-covalent association of two scFvs, yielding two Fv binding sites.
  • a triabody results from the formation of a trivalent trimer of three scFvs, yielding three binding sites, and a tetrabody is a tetravalent tetramer of four scFvs, resulting in four binding sites.
  • Several monospecific diabodies have been made using an expression vector that contains a recombinant gene construct comprising V H1 -linker-V L1 . See Holliger et al., Proc. Natl. Acad. Sci.
  • a preferred embodiment of the instant invention is a multivalent, multispecific antibody or fragment thereof comprising one or more antigen binding sites having affinity toward an EGP-1 target antigen and one or more hapten binding sites having affinity towards hapten molecules.
  • Comparative binding affinities of the mRS7, cRS7 and hRS7 antibodies thus isolated may be determined by direct radioimmunoassay.
  • RS7 can be labeled with 131 I or 125 I using the chloramines-T method (see , for example, Greenwood et al., Biochem. J., 89:123 (1963 )).
  • the specific activity of the iodinated antibody is typically adjusted to about 10 ⁇ Ci/ ⁇ g.
  • Unlabeled and labeled antibodies are diluted to the appropriate concentrations using reaction medium (HSFM supplemented with 1% horse serum and 100 ⁇ g/ml gentamicin).
  • the appropriate concentrations of both labeled and unlabeled antibodies are added together to the reaction tubes in a total volume of 100 ⁇ l.
  • a culture of ME180 cells (a human cervical carcinoma cell line) is sampled and the cell concentration determined. The culture is centrifuged and the collected cells washed once in reaction medium followed by resuspension in reaction medium to a final concentration of about 10 7 cells/ml. All procedures are carried out in the cold at 4°C.
  • the cell suspension, 100 ⁇ l, is added to the reaction tubes.
  • the reaction is carried out at 4° C. for 2 h with periodic gentle shaking of the reaction tubes to resuspend the cells. Following the reaction period, 5 ml of wash buffer (PBS containing 1% BSA) is added to each tube.
  • PBS containing 1% BSA wash buffer
  • the suspension is centrifuged and the cell pellet washed a second time with another 5 ml of wash buffer. Following centrifugation, the amount of remaining radioactivity remaining in the cell pellet is determined in a gamma counter (Minaxi, Packard Instruments, Sterling, Va.).
  • An expression vector is a DNA molecule comprising a gene that is expressed in a host cell. Typically, gene expression is placed under the control of certain regulatory elements, including constitutive or inducible promoters, tissue-specific regulatory elements, and enhancers. Such a gene is said to be "operably linked to" the regulatory elements.
  • a promoter is a DNA sequence that directs the transcription of a structural gene.
  • a structural gene is a DNA sequence that is transcribed into messenger RNA (mRNA) which is then translated into a sequence of amino acids characteristic of a specific polypeptide.
  • mRNA messenger RNA
  • a promoter is located in the 5' region of a gene, proximal to the transcriptional start site of a structural gene.
  • a promoter is an inducible promoter, then the rate of transcription increases in response to an inducing agent. In contrast, the rate of transcription is not regulated by an inducing agent if the promoter is a constitutive promoter.
  • An enhancer is a DNA regulatory element that can increase the efficiency of transcription, regardless of the distance or orientation of the enhancer relative to the start site of transcription.
  • An isolated DNA molecule is a fragment of DNA that is not integrated in the genomic DNA of an organism.
  • a cloned RS7 antigen gene is a DNA fragment that has been separated from the genomic DNA of a mammalian cell.
  • Another example of an isolated DNA molecule is a chemically-synthesized DNA molecule that is not integrated in the genomic DNA of an organism.
  • Complementary DNA cDNA
  • cDNA is a single-stranded DNA molecule that is formed from an mRNA template by the enzyme reverse transcriptase. Typically, a primer complementary to portions of mRNA is employed for the initiation of reverse transcription.
  • cDNA to refer to a double-stranded DNA molecule consisting of such a single-stranded DNA molecule and its complementary DNA strand.
  • a cloning vector is a DNA molecule, such as a plasmid, cosmid, or bacteriophage, that has the capability of replicating autonomously in a host cell.
  • Cloning vectors typically contain one or a small number of restriction endonuclease recognition sites at which foreign DNA sequences can be inserted in a determinable fashion without loss of an essential biological function of the vector, as well as a marker gene that is suitable for use in the identification and selection of cells transformed with the cloning vector. Marker genes typically include genes that provide tetracycline resistance or ampicillin resistance.
  • a recombinant host may be any prokaryotic or eukaryotic cell that contains either a cloning vector or expression vector.
  • This term also includes those prokaryotic or eukaryotic cells that have been genetically engineered to contain the cloned gene(s) in the chromosome or genome of the host cell.
  • expression refers to the biosynthesis of a gene product.
  • expression involves transcription of the structural gene into mRNA and the translation of mRNA into one or more polypeptides.
  • Contemplated in the present invention is the use of the antibodies and fragments according to the invention in a method of diagnosing or treating a malignancy in a subject comprising administering to the subject a therapeutically effective amount of a therapeutic conjugate comprising an EGP-1 MAb or fragment thereof or an antibody fusion protein according to the present invention, wherein the EGP-1MAb or fragment thereof or antibody fusion protein is bound to at least one therapeutic agent and then formulated in a pharmaceutically suitable excipient. It is also contemplated that an unconjugated (naked) EGP-1 MAb or fusion construct with other antigen-binding moieties according to the present invention also can be used as a therapeutic for cancer cells expressing EGP-1.
  • a method for diagnosing or treating cancer may comprise: administering a multivalent, multispecific antibody according to the present invention comprising one or more antigen binding sites toward a EGP-1 antigen and one or more hapten binding sites to a subject in need thereof, waiting a sufficient amount of time for an amount of the non-binding protein to clear the subject's blood stream; and then administering to the subject a carrier molecule comprising a diagnostic agent, a therapeutic agent, or a combination thereof, that binds to the binding site of the multivalent, multispecific antibody.
  • the cancer is a lung, breast, head and neck, ovarian, prostate, bladder or colon cancer.
  • Hybridoma technology for the production of monoclonal antibodies has provided a method for the production of molecular probes capable of locating or killing cancer cells.
  • Tumor imaging techniques using radiolabeled MAbs have been used to delineate cancerous invasion in a number of malignancies.
  • antibodies have been used for the radioimmunodetection of carcinoembryonic antigen in diverse tumors that express carcinoembryonic antigen, and also tumors such as melanoma, colon carcinoma, and breast carcinoma with other targeting antibodies.
  • MAbs for in vitro diagnosis is well-known. See, for example, Carlsson et al., Bio/Technology 7(6): 567 (1989 ).
  • MAbs can be used to detect the presence of a tumor-associated antigen in tissue from biopsy samples.
  • MAbs also can be used to measure the amount of tumor-associated antigen in clinical fluid samples using techniques such as radioimmunoassay, enzyme-linked immunosorbent assay, and fluorescence immunoassay.
  • Conjugates of tumor-targeted MAbs and toxins can be used to selectively kill cancer cells in vivo ( Spalding, Bio/Technology 9(8): 701 (1991 ); Goldenberg, Scientific American Science & Medicine 1(1): 64 (1994 )).
  • therapeutic studies in experimental animal models have demonstrated the anti-tumor activity of antibodies carrying cytotoxic radionuclides. ( Goldenberg et al., Cancer Res. 41: 4354 (1981 ), Cheung et al., J. Nat'l Cancer Inst. 77: 739 (1986 ), and Senekowitsch et al., J. Nucl. Med. 30: 531 (1989 )).
  • Stein et al. Antibody Immunoconj.
  • Phase-I therapeutic trials with some of these MAbs have been initiated for treatment of lymphoma, melanoma, and other malignancies. See, for example, DeNardo et al., Int. J. Cancer Suppl. 3: 96 (1988 ), and Goldenberg et al., J. Clin. Oncol. 9: 548 (1991 ).
  • Humanized, antibodies and fragments thereof are suitable for use in therapeutic methods and diagnostic methods. Accordingly, contemplated in the present invention is their use in a method of delivering a diagnostic or therapeutic agent, or a combination thereof, to a target comprising (i) providing a composition that comprises an anti-EGP-1 antibody according to the present invention and (ii) administering to a subject in need thereof the diagnostic or therapeutic antibody conjugate.
  • the humanized RS7 antibodies and fragments thereof of the present invention are used in methods for treating malignancies.
  • a cancer cell targeting diagnostic or therapeutic conjugate comprising an antibody component comprising an anti-EGP-1 mAb or fragment thereof or an antibody fusion protein according to the present invention that binds to the cancer cell, wherein the antibody component is bound to at least one diagnostic or at least one therapeutic agent.
  • the diagnostic conjugate comprises at least a photoactive diagnostic agent or an MRI contrast agent.
  • the diagnostic agent is a radioactive label with an energy between 60 and 4,000 keV.
  • compositions for treatment contain at least one naked or conjugated humanized, RS7 antibody according to the present invention alone or in combination with other naked or conjugated humanized, chimeric, human or other antibodies of the present invention, or other naked or conjugated humanized, chimeric or human antibodies not disclosed herein.
  • the present invention also contemplates the use of the antibodies and fragments according to the invention for administration of a conjugated or naked antibody with a therapeutic agent such as an immunomodulator, or diagnostic agent that is not conjugated to the anti-EGP-1 antibody. Naked or conjugated antibodies to the same or different epitope or antigen may be also combined with one or more of the antibodies of the present invention.
  • Multimodal therapies further include immunotherapy with a naked anti-EGP-1 antibody supplemented with administration of other antibodies in the form of naked antibodies, fusion proteins, or as immunoconjugates.
  • a humanized RS7 antibody according to the present invention may be combined with another naked humanized, chimeric RS7 or other antibody, or a humanized, chimeric RS7 or other antibody conjugated to an isotope, one or more chemotherapeutic agents, cytokines, toxins or a combination thereof.
  • the present invention contemplates treatment of a naked or conjugated EGP-1 or RS7 antibody or fragments thereof according to the present invention before, in combination with, or after other solid tumor/carcinoma associated antibodies such as anti-EGP-2, CEA, CSAp, MUC1-4, EGFR, HER2/neu, PSA, CC49 (anti-Tag 72 antibody) and PSMA antibodies.
  • solid tumor antibodies may be naked or conjugated to, inter alia , drugs, enzymes, hormones, toxins, isotopes, or immunomodulators.
  • the therapeutic conjugates may comprise an oligonucleotide, especially an antisense oligonucleotide that preferably are directed against oncogenes and oncogene products of B-cell malignancies.
  • antisense molecules inhibiting bcl-2 expression that are described in U.S. 5,734,033 (Reed ), may also be conjugated to, or form the therapeutic agent portion of an antibody fusion protein or be administered with a humanized RS7 antibody of the present invention.
  • the monospecific binding proteins described herein that are linked to diagnostic or therapeutic agents directly target RS7 positive tumors.
  • the monospecific molecules bind selectively to targeted antigens and as the number of binding sites on the molecule increases, the affinity for the target cell increases and a longer residence time is observed at the desired location. Moreover, non-antigen bound molecules are cleared from the body quickly and exposure of normal tissues is minimized.
  • a use of multispecific binding proteins is pre-targeting RS7 positive tumors for subsequent specific delivery of diagnostic or therapeutic agents.
  • the agents are carried by histamine succinyl glycyl (HSG) containing peptides.
  • the murine Monoclonal antibody designated 679 (an IgG1, K ) binds with high affinity to molecules containing the tri-peptide moiety, HSG ( Morel et al, Molecular immunology, 27, 995-1000, 1990 ).
  • 679 MAb can form a bispecific binding protein with hRS7 that binds with HSG and the target antigen.
  • Alternative haptens may also be utilized.
  • These binding proteins bind selectively to targeted antigens allowing for increased affinity and a longer residence time at the desired location.
  • non-antigen bound diabodies are cleared from the body quickly and exposure of normal tissues is minimized.
  • RS7 antibodies and fragments thereof according to the present invention can be used to treat mammalian disorders such as cancer.
  • the cancer includes, but is not limited to, lung, breast, bladder, ovarian prostate and colon cancers.
  • Delivering a diagnostic or a therapeutic agent to a target for diagnosis or treatment in accordance with the invention includes providing the anti-EGP-1 antibody or fragments thereof according to the present invention with a diagnostic or therapeutic agent and administering to a subject in need thereof with the binding protein. Diagnosis further requires the step of detecting the bound proteins with known techniques.
  • Administration of the antibodies and their fragments of the present invention with diagnostic or therapeutic agents can be effected in a mammal by intravenous, intraarterial, intraperitoneal, intramuscular, subcutaneous, intrapleural, intrathecal, perfusion through a regional catheter, or direct intralesional injection.
  • the administration may be by continuous infusion or by single or multiple boluses.
  • Doses in the range of 20 to 800 mg/m 2 are feasible, with doses between 100 and 500 mg/m 2 preferably, for therapy, and commensurately lower doses recommended for diagnostic imaging, such as 0.5 mg to 100 mg/patient. Such doses may be repeated at different frequencies, depending on the clinical situation and patient tolerance.
  • the antibody with the diagnostic or therapeutic agent may be provided as a kit for human or mammalian therapeutic and diagnostic use in a pharmaceutically acceptable injection vehicle, preferably phosphate-buffered saline (PBS) at physiological pH and concentration.
  • a pharmaceutically acceptable injection vehicle preferably phosphate-buffered saline (PBS) at physiological pH and concentration.
  • PBS phosphate-buffered saline
  • the preparation preferably will be sterile, especially if it is intended for use in humans.
  • Optional components of such kits include stabilizers, buffers, labeling reagents, radioisotopes, paramagnetic compounds, second antibody for enhanced clearance, and conventional syringes, columns, vials and the like.
  • a therapeutically effective amount of the naked humanized RS7 antibodies, or their fragments, according to the present invention can be formulated in a pharmaceutically acceptable excipent.
  • the efficacy of the naked humanized RS7 antibodies according to the present invention can also be enhanced by supplementing these naked antibodies with one or more other naked antibodies, with one or more immunoconjugates of chimeric, humanized and fully human RS7 antibodies conjugated to a therapeutic agent, such as a drug, toxin, immunomodulator, hormone, growth factor, enzyme or therapeutic radionuclides, or with one or more therapeutic agent, including a drug, toxin, immunomodulator, hormone, growth factor, enzyme, oligonucleotide, or therapeutic radionuclide, administered concurrently or sequentially or according to a prescribed dosing regimen, with the RS7 antibodies or fragments thereof.
  • a therapeutic agent such as a drug, toxin, immunomodulator, hormone, growth factor, enzyme, oligonucleotide, or therapeutic radionuclide, administered
  • the naked or conjugated RS7 antibodies of the present invention are combined with at least one cancer drug.
  • Such combination therapy can improve the effect of the drug or lower drug dose that is needed.
  • the IC 50 value was determined for Dox-RS7 and 2P-Dox-RS7 on a lung cancer cell line, Calu3, and two breast cancer cell lines, MDA468 and T47D, respectively. Calu3 and T47D cells are positive for an EGP-1 antigen and negative for a CEA antigen, and MDA468 is positive for both the EGP-1 and CEA antigens. Results indicate that the IC 50 value for Dox-RS7 is 0.04 ⁇ g/ml and for 2P-Dox-RS7 is 0.023 ⁇ g/ml.
  • conjugating a naked, human, humanized or chimeric anti-EGP-1 antibody or fragment of the present invention to a particular drug, such as 2P-Dox may help overcome multidrug resistance. This is also possible when the antibody is given in a combination with a particular drug, as described.
  • the present invention also contemplates the use of the humanized RS7 antibodies and fragments thereof according to the present invention for therapy.
  • the objective of immunotherapy is to deliver cytotoxic doses of radioactivity, toxin, cytokine, enzyme, or hormone, or drug to target cells, while minimizing exposure to non-target tissues.
  • the RS7 antigen binding proteins of the present invention can be used to treat a variety of tumors, such as of the lung, breast, bladder, ovary, uterus, stomach, and prostate.
  • any of the antibodies or antibody fusion proteins of the present invention can be conjugated with one or more therapeutic or diagnostic agents.
  • one therapeutic or diagnostic agent is attached to each antibody or antibody fragment but more than one therapeutic agent or diagnostic agent can be attached to the same antibody or antibody fragment.
  • the Fc region is absent (for example when the antibody used as the antibody component of the immunoconjugate is an antibody fragment), it is possible to introduce a carbohydrate moiety into the light chain variable region of a full-length antibody or antibody fragment. See, for example, Leung et al., J. Immunol. 154: 5919 (1995 ); Hansen et al., U.S. Patent No. 5,443,953 (1995 ), Leung et al., U.S. patent No. 6,254,868 .
  • the engineered carbohydrate moiety is used to attach the therapeutic or diagnostic agent.
  • the antibody fusion proteins of the present invention comprise two or more antibodies or fragments thereof and each of the antibodies or fragments that compose this fusion protein can contain a therapeutic agent or diagnostic agent. Additionally, one or more of the antibodies or fragments of the antibody fusion protein can have more than one therapeutic of diagnostic agent attached. Further, the therapeutic agents do not need to be the same but can be different therapeutic agents, for example, one can attach a drug and a radioisotope to the same fusion protein. Particularly, an IgG can be radiolabeled with 131 I and attached to a drug. The 131 I can be incorporated into the tyrosine of the IgG and the drug attached to the epsilon amino group of the IgG lysines. Both therapeutic and diagnostic agents also can be attached to reduced SH groups and to the carbohydrate side chains.
  • therapeutic agents include, for example, chemotherapeutic drugs such as vinca alkaloids, anthracyclines, epidophyllotoxinw, taxanes, antimetabolites, alkylating agents, antibiotics, substituted urea, enzymes, Cox-2 inhibitors, antimitotics, antiangiogenic and apoptotoic agents, particularly doxorubicin, doxorubicin analogs, methotrexate, taxol, CPT-11, camptothecans, and others from these and other classes of anticancer agents, methyl hydrazine derivative, adrenocortical suppressant, antagonist, endostatin, taxol, and the like.
  • chemotherapeutic drugs such as vinca alkaloids, anthracyclines, epidophyllotoxinw, taxanes, antimetabolites, alkylating agents, antibiotics, substituted urea, enzymes, Cox-2 inhibitors, antimitotics, antiangiogenic and apoptotoic
  • cancer chemotherapeutic drugs for the preparation of immunoconjugates and antibody fusion proteins include nitrogen mustards, ethylenimine derivatives, alkyl sulfonates, nitrosoureas, triazenes, folic acid analogs, COX-2 inhibitors, pyrimidine analogs, purine analogs, platinum coordination complexes, hormones, tyrosine kinase inhibitors, such as those that inhibit a EGF-receptor tyrosine kinase, a BCR ABL tyrosine kinase or a VEGF-receptor tyrosine kinase, and the like.
  • Suitable chemotherapeutic agents are described in REMINGTON'S PHARMACEUTICAL SCIENCES, 19th Ed. (Mack Publishing Co. 1995 ), and in GOODMAN AND GILMAN'S THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, 7th Ed. (MacMillan Publishing Co. 1985 ), as well as revised editions of these publications.
  • Other suitable chemotherapeutic agents, such as experimental drugs, are known to those of skill in the art.
  • a toxin such as Pseudomonas exotoxin
  • Pseudomonas exotoxin may also be complexed to or form the therapeutic agent portion of an immunoconjugate of the RS7 and hRS7 antibodies of the present invention.
  • Other toxins suitably employed in the preparation of such conjugates or other fusion proteins include ricin, abrin, ribonuclease (RNase), DNase I, Staphylococcal enterotoxin-A, pokeweed antiviral protein, gelonin, diphtherin toxin, Pseudomonas exotoxin, and Pseudomonas endotoxin.
  • an immunomodulator such as a cytokine may also be conjugated to, or form the therapeutic agent portion of the EGP-1, RS7 and hRS7 immunoconjugate, or be administered unconjugated to the humanized RS7 antibodies or fragments thereof of the present invention.
  • the term "immunomodulator” includes cytokines, stem cell growth factors, lymphotoxins, such as tumor necrosis factor (TNF), and hematopoietic factors, such as interleukins (e.g. , interteukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, and IL-21), colony stimulating factors (e.g.
  • interferons e.g. , interferons- ⁇ , - ⁇ and - ⁇
  • S1 factor the stem cell growth factor designated "S1 factor”
  • erythropoietin and thrombopoietin or a combination thereof.
  • suitable immunomodulator moieties include IL-2, IL-6, IL-10, IL-12, IL-18, IL-21, interferon- ⁇ , TNF- ⁇ , and the like.
  • subjects can receive naked EGP-1 or RS7 antibodies and a separately administered cytokine, which can be administered before, concurrently or after administration of the naked RS7 antibodies.
  • the RS7 antibody may also be conjugated to the immunomodulator.
  • the immunomodulator may also be conjugated to a hybrid antibody consisting of one or more antibodies binding to different antigens.
  • a therapeutic or diagnostic agent can be attached at the hinge region of a reduced antibody component via disulfide bond formation.
  • such peptides can be attached to the antibody component using a heterobifunctional cross-linker, such as N- succinyl 3-(2-pyridyldithio)proprionate (SPDP). Yu et al., Int. J. Cancer 56: 244 (1994 ). General techniques for such conjugation are well-known in the art.
  • the therapeutic or diagnostic agent can be conjugated via a carbohydrate moiety in the Fc region of the antibody.
  • the carbohydrate group can be used to increase the loading of the same peptide that is bound to a thiol group, or the carbohydrate moiety can be used to bind a different peptide.
  • a radiolabeled antibody, immunoconjugate, or fragments thereof may comprise a ⁇ -emitting radioisotope or a positron-emitter useful for diagnostic imaging.
  • Suitable radioisotopes particularly in the energy range of 25 to 4,000 keV, include 131 I 123 I 124 I, 86 Y, 62 Cu, 64 Cu, 67 Ga, 68 Ga, 99m Tc, 94m Tc, 18 F, 11 C, 13 N, 15 O, 75 Br, and the like. See for example, U.S. Patent Application entitled "Labeling Targeting Agents with Gallium-68"- Inventors G.L.Griffiths and W.J. McBride, (U.S. Provisional Application No.
  • the energy range for diagnostic and therapeutic radionuclides is 25-4,000 keV.
  • Other useful radionuclides include 90 Y, 111 In, 125 I, 3 H, 35 S, 14 C, 196 Re, 188 Re, 189 Re, 177 Lu, 67 Cu, 212 Bi, 213 Bi, 211 At, 198 Au, 224 Ac, 126 I, 133 I, 77 Br, 113m In, 95 Ru, 97 Ru, 103 Ru, 105 Ru, 107 Hg, 203 Hg, 94m Tc, 121m Te, 122m Te, 125m Te, 165 Tm, 167 Tm, 168 Tm, 111 Ag, 197 Pt, 109 Pd, 32 P, 33 P, 47 Sc, 153 Sm, 177 Lu, 105 Rh, 142 Pr, 143 Pr, 161
  • 67 Cu considered one of the more promising radioisotopes for radioimmunotherapy due to its 61.5 hour half-life and abundant supply of beta particles and gamma rays, can be conjugated to an RS7 antigen binding protein using the chelating agent, p-bromoacetamido-benzyl- tetraethylaminetetraacetic acid (TETA). Chase, supra.
  • 90 Y which emits an energetic beta particle, can be coupled to an RS7 antigen binding protein using diethylenetriaminepentaacetic acid (DTPA).
  • DTPA diethylenetriaminepentaacetic acid
  • DTPA diethylenetriaminepentaacetic acid
  • RS7 antibodies or fragments thereof of the present invention that have a boron addend-loaded carrier for thermal neutron activation therapy will normally be effected in similar ways. However, it will be advantageous to wait until non-targeted RS7 immunoconjugate clears before neutron irradiation is performed. Clearance can be accelerated using an antibody that binds to the RS7 antibody. See U.S. patent No. 4,624,846 for a description of this general principle.
  • boron addends such as carboranes, can be attached to RS7 antibodies. Carboranes can be prepared with carboxyl functions on pendant side chains, as is well-known in the art.
  • Attachment of carboranes to a carrier can be achieved by activation of the carboxyl groups of the carboranes and condensation with amines on the carrier.
  • the intermediate conjugate is then conjugated to the RS7 antibody.
  • a boron addend is activated by thermal neutron irradiation and converted to radioactive atoms that decay by ⁇ -emission to produce highly toxic, short-range effects.
  • the present invention includes the use of the antibodies or fragments according to the invention in methods of diagnosing cancer in a subject. Diagnosis may be accomplished by administering a diagnostically effective amount of a diagnostic conjugate, formulated in a pharmaceutically suitable excipient, and detecting said label.
  • a diagnostic conjugate formulated in a pharmaceutically suitable excipient
  • radioactive and non-radioactive agents can be used as diagnostic agents.
  • a suitable non-radioactive diagnostic agent is a contrast agent suitable for magnetic resonance imaging, computed tomography or ultrasound.
  • Magnetic imaging agents include, for example, non-radioactive metals, such as manganese, iron and gadolinium, complexed with metal-chelate combinations that include 2-benzyl-DTPA and its monomethyl and cyclohexyl analogs, when used along with the antibodies of the invention. See U.S. Serial No. 09/921,290 filed on October 10, 2001 .
  • a method of diagnosing a malignancy in a subject comprising (i) performing an in vitro diagnosis assay on a specimen from the subject with a composition comprising a naked anti-EGP-1 MAb or fragment thereof or a naked antibody fusion protein according to the present invention.
  • RT-PCR and immunoassay in vitro diagnosis methods can be used to detect the presence of minute amounts of EGP-1 in tissues, blood and other body fluids as a useful diagnostic/detection method.
  • Immunohistochemistry can be used to detect the presence of EOP-1 in a cell or tissue.
  • the malignancy that is being diagnosed is a cancer.
  • the cancer is selected from the group of lung, prostate, ovarian, breast, colon and bladder.
  • a chelator such as DTPA, DOTA, TETA, or NOTA or a suitable peptide, to which a detectable label, such as a fluorescent molecule, or cytotoxic agent, such as a heavy metal or radionuclide, can be conjugated.
  • a therapeutically useful immunoconjugate can be obtained by conjugating a photoactive agent or dye to an antibody fusion protein.
  • Fluorescent compositions such as fluorochrome, and other chromogens, or dyes, such as porphyrins sensitive to visible light, have been used to detect and to treat lesions by directing the suitable light to the lesion. In therapy, this has been termed photo radiation, phototherapy, or photodynamic therapy ( Jori et al.
  • the present invention contemplates the therapeutic use of immunoconjugates comprising photoactive agents or dyes.
  • Contrast agents such as a MRI contrast agent, a paragmagnetic ion and an ultrasound enhancing agent are also contemplated in the present invention.
  • gadolinium ions, lanthanum ions, manganese ions or other comparable label, CT contrast agents, and ultrasound contrast agents are suitable for use in the present invention.
  • the ultrasound enhancing agent is a liposome that comprises a humanized RS7 IgG or fragment thereof.
  • the liposome is gas filled.
  • the RS7 antibodies and fragments thereof of the present invention are administered to a patient in a therapeutically effective amount.
  • An antibody is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant.
  • An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient patient.
  • the present invention contemplates the use of RS7 antibodies, including RS7 and hRS7 antibodies and fragments thereof, to screen biological samples in vitro for the presence of the RS7 antigen.
  • the RS7 antibody may be utilized in liquid phase or bound to a solid-phase carrier, as described below. Also, see Stein et al. (1993), supra, and Stein et al., Cancer Res. 49: 32 (1989 ).
  • a screening method for determining whether a biological sample contains the RS7 antigen is the radioimmunoassay (RIA).
  • RIA radioimmunoassay
  • the substance under test is mixed with RS7 antigen MAb in the presence of radiolabeled RS7 antigen.
  • concentration of the test substance will be inversely proportional to the amount of labeled RS7 antigen bound to the MAb and directly related to the amount of free labeled RS7 antigen.
  • Other suitable screening methods will be readily apparent to those of skill in the art.
  • in vitro assays can be performed in which an RS7 antigen binding protein is bound to a solid-phase carrier.
  • MAbs can be attached to a polymer, such as aminodextran, in order to link the MAb to an insoluble support such as a polymer-coated bead, a plate or a tube.
  • RS7 antigen binding protein and RS7 antigen may be varied, depending on various factors including the concentration of the RS7 antigen in the sample, the nature of the sample, and the like.
  • the binding activity of a sample of RS7 antigen binding protein may be determined according to well known methods. Those skilled in the art will be able to determine operative and optimal assay conditions for each determination by employing routine experimentation.
  • the presence of the RS7 antigen in a biological sample can be determined using an enzyme-linked immunosorbent assay (ELISA).
  • ELISA enzyme-linked immunosorbent assay
  • a pure or semipure antigen preparation is bound to a solid support that is insoluble in the fluid or cellular extract being tested and a quantity of detectably labeled soluble antibody is added to permit detection and/or quantitation of the binary complex formed between solid-phase antigen and labeled antibody.
  • a double-determinant ELISA also known as a “two-site ELISA” or “sandwich assay”
  • the double-determinant ELISA is preferred to the direct competitive ELISA for the detection of an antigen in a clinical sample. See, for example, the use of the double-determinant ELISA for quantitation of the c-myc oncoprotein in biopsy specimens. Field et al., Oncogene 4: 1463 (1989 ); Spandidos et al., AntiCancer Res. 9: 821 (1989 ).
  • an antibody fragment is a portion of an antibody such as F(ab') 2 , F(ab) 2 , Fab', Fab, and the like.
  • an antibody fragment is a portion of an RS7 MAb that binds to an epitope of the RS7 antigen.
  • antibody fragment also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a complex.
  • antibody fragments include isolated fragments consisting of the light chain variable region, "Fv" fragments consisting of the variable regions of the heavy and light chains, and recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker.
  • An antibody fusion protein is a polyspecific antibody composition comprising at least two substantially monospecific antibodies or antibody fragment, wherein at least two of the antibodies or antibody fragments bind to different epitopes of the RS7 antigen.
  • An RS7 fusion protein also includes a conjugate of an antibody fusion protein with a diagnostic or therapeutic agent.
  • the term RS7 antibody includes humanized, antibodies, antibody fragments thereof, immunoconjugates and fragments thereof and antibody fusion proteins.
  • finely minced tissue from a biopsy sample is lyophilized and resuspended in lysis buffer (100 mM NaCl, 50 mM Tris-HCl, pH 7.4) containing 1% nonidet-p40 (NP40), 0.6 ⁇ l/ml aprotinin, 0.2 mM phenyl methyl sulphonyl fluoride, 0.1 ⁇ g/ml leupeptin and 1 mM EDTA at a concentration of 10-20 mg tissue (wet weight) per 500 ⁇ l solution.
  • lysis buffer 100 mM NaCl, 50 mM Tris-HCl, pH 7.4
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • NP40 nonidet-p40
  • the soluble extract is added to microtiter plate wells containing an adsorbed RS7 antigen MAb as the capture antibody. Captured RS7 antigen is then recognized by a second RS7 antigen MAb, which has been coupled with alkaline phosphatase. The amount of bound alkaline phosphatase, proportional to the amount of RS7 antigen in the extract, is detected colormetrically using a chromogenic substrate, such as p- nitrophenylphosphate:
  • a double-determinant ELISA for the RS7 antigen can be performed using horse radish peroxidase.
  • Other variations of sample preparation and the double-determinant ELISA can be devised by those of skill in the art with routine experimentation.
  • the soluble antibody or antibody fragment must bind to an RS7 epitope that is distinct from the epitope recognized by the capture antibody.
  • the soluble antibody can be the RS7 MAb, while the capture antibody can be MR23.
  • the soluble antibody can be MR23, while the capture antibody can be the RS7 MAb.
  • the double-determinant ELISA can be performed to ascertain whether the RS7 antigen is present in a biopsy sample.
  • the assay can be performed to quantitate the amount of RS7 antigen that is present in a clinical sample of body fluid.
  • the quantitative assay can be performed by including dilutions of purified RS7 antigen. A method for purifying the RS7 antigen is illustrated below.
  • kits may comprise a carrier means that is compartmentalized to receive in close confinement one or more container means such as vials, tubes and the like, each of said container means comprising the separate elements of the immunoassay.
  • a container means containing the capture antibody immobilized on a solid phase support there may be a container means containing the capture antibody immobilized on a solid phase support, and a further container means containing detectably labeled antibodies in solution.
  • Further container means may contain standard solutions comprising serial dilutions of RS7 antigen.
  • the standard solutions of RS7 antigen may be used to prepare a standard curve with the concentration of RS7 antigen plotted on the abscissa and the detection signal on the ordinate.
  • the results obtained from a sample containing RS7 antigen may be interpolated from such a plot to give the concentration of RS7 antigen in the biological sample.
  • RS7 antibodies and their fragments of the present invention also can be used to detect the presence of the RS7 antigen in tissue sections prepared from a histological specimen. Such in situ detection can be used to determine the presence of the RS7 antigen and to determine the distribution of the RS7 antigen in the examined tissue. In situ detection can be accomplished by applying a detectably-labeled RS7 antigen binding protein to frozen tissue sections. Studies indicate that the RS7 antigen is not preserved in paraffin-embedded sections. Stein et al. (1993), supra. General techniques of in situ detection are well-known to those of ordinary skill.
  • RS7 antibodies and their fragments can be detectably labeled with any appropriate detection agent, for example, a radioisotope, an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent labels or a paramagnetic label.
  • detection agent for example, a radioisotope, an enzyme, a fluorescent label, a chemiluminescent label, a bioluminescent labels or a paramagnetic label.
  • the marker moiety can be a radioisotope that is detected by such means as the use of a gamma counter or a scintillation counter or by autoradiography.
  • the diagnostic conjugate is a gamma-, beta- or a positron-emitting isotope.
  • a marker moiety in the present description refers to molecule that will generate a signal under predetermined conditions. Examples of marker moieties include radioisotopes, enzymes, fluorescent labels, chemiluminescent labels, bioluminescent labels and paramagnetic labels.
  • a diagnostic or therapeutic agent is a molecule or atom which is conjugated to an antibody moiety to produce a conjugate which is useful for diagnosis and for therapy.
  • diagnostic or therapeutic agents include drugs, toxins, chelators, dyes, chromagens, boron compounds, and marker moieties.
  • Isotopes that are particularly useful for the purpose of the present invention are 3 H, 131 I, 35 S; 14 C, and preferably 125 I.
  • examples of other radionuclides are, for example, 90 Y, 111 In, 99m Tc, 186 Re, 188 Re, 177 Lu, 67 Cu, 212 Bi, 213 Bi, and 211 At. Additional radionuclides are also available as diagnostic and therapeutic agents. Suitable diagnostic imaging isotopes are usually in the range of 25 to 4,000 keV, while suitable therapeutic radionuclides are usually in the range of 60 to 700 keV.
  • the RS7 antibodies and their fragments of the present invention also can be labeled with a fluorescent compound.
  • the presence of a fluorescently-labeled MAb is determined by exposing the RS7 antigen binding protein to light of the proper wavelength and detecting the resultant fluorescence.
  • Fluorescent labeling compounds include fluorescein isothiocyanate, rhodamine, phycoerytherin, phycocyanin, allophycocyanin, o-phthaldehyde and fluorescamine. Fluorescently-labeled RS7 antigen binding proteins are particularly useful for flow cytometry analysis.
  • RS7 antibodies and their fragments can be detectably labeled by coupling the RS7 antigen binding protein to a chemiluminescent compound.
  • the presence of the chemiluminescent-tagged MAb is determined by detecting the presence of luminescence that arises during the course of a chemical reaction.
  • chemiluminescent labeling compounds include luminol, isoluminol, an aromatic acridinium ester, an imidazole, an acridinium salt and an oxalate ester.
  • Bioluminescent compound can be used to label RS7 antibodies and fragments thereof the present invention.
  • Bioluminescence is a type of chemiluminescence found in biological systems in which a catalytic protein increases the efficiency of the chemiluminescent reaction. The presence of a bioluminescent protein is determined by detecting the presence of luminescence.
  • Bioluminescent compounds that are useful for labeling include luciferin, luciferase and aequorin.
  • RS7 antibodies and fragments thereof can be detectably labeled by linking the RS7 antibody to an enzyme.
  • the enzyme moiety reacts with the substrate to produce a chemical moiety which can be detected, for example, by spectrophotometric, fluorometric or visual means.
  • Examples of enzymes that can be used to detectably label RS7 antibody include malate dehydrogenase, staphylococcal nuclease, delta-V-steroid isomerase, yeast alcohol dehydrogenase, ⁇ -glycerophosphate dehydrogenase, triose phosphate isomerase, horseradish peroxidase, alkaline phosphatase, asparaginase, glucose oxidase, ⁇ -galactosidase, ribonuclease, urease, catalase, glucose-6-phosphate dehydrogenase, glucoamylase and acetylcholinesterase.
  • RS7 antibodies, fragments thereof and fusion proteins also can be labeled with paramagnetic ions for purposes of in vivo diagnosis.
  • Contrast agents that are particularly useful for magnetic resonance imaging comprise Gd, Mn, Dy or Fe ions.
  • RS7 antibodies and fragments thereof can also be conjugated to ultrasound contrast/enhancing agents.
  • the ultrasound contrast agent is a liposome that comprises a humanized RS7 IgG or fragment thereof. Also preferred, the ultrasound contrast agent is a liposome that is gas filled.
  • a bispecific antibody can be conjugated to a contrast agent
  • the bispecific antibody may comprise more than one image-enhancing agent for use in ultrasound imaging.
  • the contrast agent is a liposome.
  • the liposome comprises a bivalent DTPA-peptide covalently attached to the outside surface of the liposome.
  • the liposome is gas filled.
  • RS7 antibodies The binding of marker moieties to RS7 antibodies can be accomplished using standard techniques known to the art. Typical methodology in this regard is described by Kennedy et al., Clip Chim. Acta 70: 1 (1976 ), Schurs et al., Clin. Chim. Acta 81: 1 (1977 ), Shih et al., Int'l J. Cancer 46: 1101 (1990 ), Stein et al. (1990), supra, and Stein et al. (1993), supra. Also, see generally, Coligan.
  • in vitro and in situ detection methods may be used to assist in the diagnosis or staging of a pathological condition.
  • such methods can be used to detect tumors that express the RS7 antigen including tumors of the lung, breast, bladder, ovary, uterus, stomach, and prostate.
  • the present invention also contemplates the use of RS7 antibodies according to the present invention for in vivo diagnosis.
  • the method of diagnostic imaging with radiolabeled MAbs is well-known.
  • antibodies are labeled with a gamma-emitting radioisotope and introduced into a patient.
  • a gamma camera is used to detect the location and distribution of gamma-emitting radioisotopes.
  • radioisotopes may be bound to the RS7 antibody either directly, or indirectly by using an intermediary functional group.
  • intermediary functional groups include chelators such as ethylenediaminetetraacetic acid and diethylenetriaminepentaacetic acid. For example, see Shih et al., supra, and U.S. patent No. 5,0.57,313 .
  • the radiation dose delivered to the patient is maintained at as low a level as possible through the choice of isotope for the best combination of minimum half-life, minimum retention in the body, and minimum quantity of isotope which will permit detection and accurate measurement.
  • radioisotopes that can be bound to RS7 antibody and are appropriate for diagnostic imaging include 99m Tc and 111 In.
  • Control release preparations can be prepared through the use of polymers to complex or adsorb the RS7 antibody.
  • biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood et al., Bio/Technology 10: 1446 (1992 ). The rate of release of an RS7 antibody from such a matrix depends upon the molecular weight of the RS7 antibody, the amount of RS7 antibody within the matrix, and the size of dispersed particles. Saltzman et al., Biophys. J. 55: 163 (1989 ); Sherwood et al., supra. Other solid dosage forms are described in REMINGTON'S PHARMACEUTICAL SCIENCES, 18th ed. (1990 ).
  • the humanized RS7 antibodies according to the present invention to be delivered to a subject can consist of the antibody alone, immunoconjugate, fusion protein, or can comprise one or more pharmaceutically suitable excipients, one or more additional ingredients, or some combination of these.
  • the immunoconjugate, naked antibody, fusion protein, and fragments thereof of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby the immunoconjugate or naked antibody is combined in a mixture with a pharmaceutically suitable excipient.
  • a pharmaceutically suitable excipient Sterile phosphate-buffered saline is one example of a pharmaceutically suitable excipient.
  • Other suitable excipients are well-known to those in the art.
  • the immunoconjugate or naked antibody of the present invention can be formulated for intravenous administration via, for example, bolus injection or continuous infusion.
  • Formulations for injection can be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
  • the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • Control release preparations can be prepared through the use of polymers to complex or adsorb the immunoconjugate or naked antibody.
  • biocompatible polymers include matrices of poly(ethylene-co-vinyl acetate) and matrices of a polyanhydride copolymer of a stearic acid dimer and sebacic acid. Sherwood et al., BiolTechnology 10: 1446 (1992 ). The rate of release of an immunoconjugate or antibody from such a matrix depends upon the molecular weight of the immunoconjugate or antibody, the amount of immunoconjugate, antibody within the matrix, and the size of dispersed particles.
  • the immunoconjugate, antibody fusion protein, naked antibody, and fragments thereof may also be administered to a mammal subcutaneously or even by other parenteral routes.
  • the anti-EGP-1 antibody or fragment thereof according to the present invention is administered in a dosage of 10 to 2000 milligrams protein per dose.
  • the administration may be by continuous infusion or by single or multiple boluses.
  • the dosage of an administered immunoconjugate, fusion protein or naked antibody for humans will vary depending upon such factors as the patient's age, weight, height, sex, general medical condition and previous medical history.
  • a dosage of immunoconjugate, antibody fusion protein or naked antibody that is in the range of from about 1mg/kg to 20 mg/kg as a single intravenous infusion, although a lower or higher dosage also may be administered as circumstances dictate.
  • This dosage may be repeated as needed, for example, once per week for 4-10 weeks, preferably once per week for 8 weeks, and more preferably, once per week for 4 weeks. It may also be given less frequently, such as every other week for several months.
  • the dosage may be given through various parenteral routes, with appropriate adjustment of the dose and schedule.
  • the RS7 antibodies of the present invention can be formulated according to known methods to prepare pharmaceutically useful compositions, whereby RS7 antibodies are combined in a mixture with a pharmaceutically acceptable carrier.
  • a composition is said to be a "pharmaceutically acceptable carrier” if its administration can be tolerated by a recipient patient.
  • Sterile phosphate-buffered saline is one example of a pharmaceutically acceptable carrier.
  • Other suitable carriers are well-known to those in the art. See, for example, REMINGTON'S PHARMACEUTICAL SCIENCES, 18th Ed. (1990 ).
  • the immunoconjugate, fusion protein, or naked antibody may be administered to a mammal in a therapeutically effective amount.
  • a suitable subject for the present invention is usually a human, although a non-human animal subject is also contemplated.
  • An antibody preparation is said to be administered in a "therapeutically effective amount" if the amount administered is physiologically significant
  • An agent is physiologically significant if its presence results in a detectable change in the physiology of a recipient mammal.
  • Total cytoplasmic RNA and mRNA was prepared from RS7-producing hybridoma cells.
  • the genes encoding V ⁇ and VH sequences were cloned by RT-PCR and 5'RACE and the sequences were determined by DNA sequencing. Multiple independent clones were sequenced to eliminate possible errors resulting from the PCR reaction. Sequence analyses revealed presence of two V ⁇ (#1 and #23) and one VH (RS7VH) transcripts. Combining each of the putative murine V ⁇ with the VH, two chimeric Abs (cAbs), containing human constant region domains were generated and expressed in Sp2/0 cells by transfection.
  • cAbs chimeric Abs
  • cAb-producing clones were identified by screening the cell culture supernatants of the transfected cell clones by ELISA. Positive clones were expanded and cAbs were purified from the cell culture supernatants.
  • the Ag-binding assay showed that only the cAb composed of Vic#23 and VH, cAb-Vx#23, bound to microwells coated with the crude membrane fraction of ME180, a human cervical carcinoma cell (ATCC, Rockville, MD) ( Figure 1 ).
  • the cAb with the combination of V ⁇ #1 and VH, cAb-V ⁇ #1, did not show binding to the Ag-coated wells. Therefore, the immunoreactive cAb (with V ⁇ #23) was designated as cRS7.
  • the cloned murine V H and the functional V ⁇ (#23) sequences as the final PCR products were designated as RS7Vk ( Figure 2A ) and RS7VH ( Figure 2B ), respectively.
  • a competitive ELISA binding assay was used to evaluate the binding affinity of engineered cRS7. Briefly, constant amount of biotinylated murine RS7 is mixed with varying concentrations (0.01-100 ⁇ g/ml) of testing Abs (RS7 or cRS7), and added into Ag-coated microwells, and incubated at room temperature for 1 h. After washing, HRP conjugated streptavidin is added and incubated for 1 h at room temperature.
  • the amount of HRP-conjugated streptavidin bound to the Ag-bound biotinylated RS7 was revealed by reading OD 490 after the addition of a substrate solution containing 4 mM ortho-phenylenediamine dihydrochloride and 0.04% H 2 O 2 .
  • cRS7 and murine RS7 competed equally well for the binding of biotinylated murine RS7 to the antigen coated wells, thus confirmed the authenticity of the V ⁇ and VH sequences obtained ( Fig. 1 ).
  • hRS7VHA 176-mer
  • hRS7VHB 168-mer
  • hRS7VHA represents nt 23 to 198 of the hRS7VH domain
  • hRS7VHB represents the minus strand of the hRS7VH domain complementary to nt 174 to 340.
  • the 3'-terminal sequences (23 nt residues) of hRS7VHA and B are complementory to each other. Under defined PCR condition, 3'-ends of hRS7VHA and B anneal to form a short double stranded DNA flanked by the rest of the long oligonucleotides. Each annealed end serves as a primer for the transcription of the single stranded DNA, resulting in a double strand DNA composed of the nt 23 to 340 of hRS7VH. This DNA was further amplified in the presence of two short oligonucleotides, hRS7VHBACK and hRS7VBFOR to form the full-length hRS7VH.
  • hRS7VHA and B (determined empirically) was amplified in the presence of 10 ⁇ l of 10x PCR Buffer (500 mM KCl, 100 mM Tris.HCL buffer, pH 8.3, 15 mM MgCl 2 ), 2 ⁇ mol of hRS7VHBACK and hRS7VHFOR, and 2.5 units of Taq DNA polymerase (Perkin Elmer Cetus, Norwalk, Ct).
  • This reaction mixture was subjected to 3 cycle of PCR reaction consisting of denaturation at 94°C for 1 minute, annealing at 45°C for 1 minute, and polymerization at 72°C for 1.5 minutes, and followed by 27 cycles of PCR reaction consisting of denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute, and polymerization at 72°C for 1 minute.
  • Double-stranded PCR amplified product for hRS7VH was gel-purified, restriction-digested with PstI and BstEII and cloned into the complementary PstI/BstEII sites of the heavy chain staging vector, VHpBS2.
  • hRS7VKA (156-mer) and hRS7VKB (155-mer) were synthesize as described above.
  • hRS7VKA and B were amplified by two short oligonucleotides hRS7VKBACK and hRS7VKFOR as described above.
  • HRS7VKA represents nt 20 to 175 of the hRS7V ⁇ domain.
  • hRS7VKB represents the minus strand of the hRS7V ⁇ domain complementary to nt 155 to 320.
  • hRS7pdHL2 was constructed by sequentially subcloning the XbaI-BamHI and XhoI/BamHI fragments of hRS7V ⁇ and VH, respectively, into pdHL2 as described above.
  • Approximately 30 ⁇ g of the expression vectors for hRS7 were linearized by digestion with SalI and transfected into Sp2/0-Ag14 cells by electroporation (450V and 25 ⁇ F). The transfected cells were plated into 96-well plates for 2 days and then selected for drug-resistance by adding MTX into the medium at a final concentration of 0.025 ⁇ M. MTX-resistant colonies emerged in the wells 2-3 weeks. Supernatants from colonies surviving selection were screened for human Ab secretion by ELISA assay.
  • ME180 cell membrane extract coated plate An ELISA competitive binding assay using ME180 cell membrane extract coated plate was used to assess the immunoreactivity of hRS7.as described ( Stein et al., Int. J. Cancer 55:938-946(1993 )).
  • ME180 cell membrane fraction was prepared by sonication and centrifugation. The crude membrane extract was coated in 96-well flat bottomed PVC plate by centrifugation and fixed with 0.1% glutaraldehyde. Constant amount of the biotinylated murine RS7 mixed with varying concentrations of mRS7, cRS7 or hRS7 was added to the membrane coated wells and incubated at room temperature for 1-2 h.
  • HRP-conjugated streptavidin was added and incubated for 1 h at room temperature.
  • the amount of HRP-conjugated streptavidin bound to the membrane-bound biotinylated mRS7 was revealed by reading A 490 nm after the addition of a substrate solution containing 4 mM ortho-phenylenediamine dihydrochloride and 0.04% H 2 O 2 .
  • hRS7 IgG exhibited comparable binding activities with that of mRS7 and cRS7, confirming the binding affinity of RS7 was preserved in humanization.
  • the residualizing moiety (IMP-R4, IMP-R5 or IMP-R8) was radioiodinated, and coupled to disulfide-reduced hRS7 along the procedure described elsewhere ( Govindan SV, et al. Bioconjugate Chem. 1999;10:231-240 ). See Figure 9 .
  • tumors were propagated in 5-8 week old female nude mice by subcutaneous injection of ⁇ 2.3 ⁇ 10 7 cultured MDA-MB-468 cells, and the animals were used after one month when the tumor size reached ⁇ 01-to-0.2 cm 3 .
  • CT method 20-25 ⁇ Ci of 131 I-MAb
  • tumor growth patterns under various formats were studied to determine the optimal method for steady growth of tumor. It was concluded that the method used for targeting experiments was optimal after about 8-weeks of tumor growth, and 30-50 % of the animals could be used based on the tumor growth profiles.
  • the tumor-bearing animals were injected i.v. with 131 I-IMPR4-hRS7 was the agent examined, and compared with directly radioiodinated material, 131 I-hRS7. Baseline body weights were compared with weekly measurements of body weights and tumor volumes. Animals were sacrificed when tumors reached 3 cm 3 . All animal experiments were carried out in accord with IACUC-approved protocols.
  • % injected dose per gram of tumor on day-7 were 41.6 ⁇ 3.0 %, 32.2 ⁇ 11.6 % and 24.7 ⁇ 8.5 % for 125 I-IMP-R4-hRS7, 125 I-IMP-R5-hRS7 and 125 I-IMP-R8-hRS7, respectively, while that for directly labeled 131 I-hRS7 at the same time-point in each of the dual-labeled experiments were 5.9 ⁇ 0.9 %, 6.2 ⁇ 2.1 % and 6.7 ⁇ 2.3 %.
  • Tumor-to-nontumor ratios for the same time-point were 1.7-to-7.6-fold higher with 125 I-IMP-R4-hRS7, 1.7-to-6.0-fold higher with 125 I-IMP-R5-hRS7, and 2.0-to-4.8-fold higher with 125 I-IMP-R8-hRS7 compared to the ratios with 131 I-hRS7 (data not shown).
  • I-IMP-R5 1.5 ⁇ 0.3 0.8 ⁇ 0.04 0.6 ⁇ 0.1 0.2 ⁇ 0.1 131 I(CT) 1.1 ⁇ 0.2 0.6 ⁇ 0.02 0.5 ⁇ 0.1 0.3 ⁇ 0.1 Lg. Int.
  • Table-2 Calculated radiation doses due to variously radioiodinated hRS7 in the MDA-MB-468 tumor model Organ Model cGy normalized to 1500 cGy to Blood Group I Group II Group III IMP-R4 CT IMP-R5 CT IMP-R8 CT Tumor (Trap 0 point 0) 6995 1613 5187 1506 4000 1206 Liver Exp 674 456 398 449 497 505 Spleen Exp 535 315 336 313 384 356 Kidney Exp 1063 402 867 361 761 394 Lungs Exp 450 392 450 422 506 473 Blood(or g) Exp 1500 1500 1500 1500 1500 1500 1500 1500 Stomach Exp 104 144 84 118 101 128 Sm Int Exp 148 124 131 119 130 121 Lg Int Exp 163 108 136 86 140 97 Muscle Exp 112 99 105 100 97 93 Bone Exp 486 151 244 149 245
  • MTD Maximum-tolerated-dose
  • FIG. 11 shows tumor volumes (cm 3 ) for individual animals in each group, and the bottom panel indicates mean tumor volumes in two formats. There were three deaths in the untreated group. Tumor growth control is significantly better for the residualizing label group compared to the conventional label and the untreated groups, as determined by the student-t test on the area under the curves (AUC) for mean tumor volumes (MTV) up to day-49.
  • AUC area under the curves
  • MTV mean tumor volumes up to day-49.
  • significance (p values) for differences in AUCs of MTVs due to therapy with 131 I-IMP-R4-hRS7, with the respective p values for tumor volume differences before therapy (day -2) given in parentheses are as follows.
  • the treatments were well tolerated.
  • the mean body weights of IMP-R4 group on day -2 was 21.93 ⁇ 2.03 and that on day 49 was 23.68 ⁇ 1.81; for 'CT' group, the mean body weights were 21.77 ⁇ 2.21 and 23.90 ⁇ 2.64 on days -2 and 49, respectively.
  • Myelotoxicities of the treated groups, as determined by blood cell counts, are shown in Figure-12. Briefly: With 131 I-IMP-R4-hRS7, nadirs of 34%, 7% and 61% of the control levels for WBC, lymphocite and neutrophil counts, respectively, were reached one week after the administration of the agent.
  • Example 5 Treatment of a breast cancer patient with Y-90 humanized RS7 mAb and with naked humanized RS7 mAb:
  • her white blood cell and platelet counts have decreased by approximately 50%, but recuperate by 9 weeks post-therapy.
  • a ca. 30% decrease in pulmonary and nodal metastases has been measured by computed tomography.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (85)

  1. Anticorps humanisé RS7, ou un fragment de celui-ci, qui reconnait la glycoprotéine-1 épithéliale, dans lequel les CDR de la région variable de la chaîne lourde de l'anticorps, ou du fragment de celui-ci, comprennent CDR1 comprenant une séquence d'acides aminés NYGMN ; CDR2 comprenant une séquence d'acides aminés WINTYTGEPTYTDDFKG et CDR3 comprenant une séquence d'acides aminés GGFGSSYWYFDV, et dans lequel les régions déterminant la complémentarité (CDR) de la région variable de la chaîne légère de l'anticorps, ou du fragment de celui-ci, comprennent CDR1 comprenant une séquence d'acides aminés KASQDVSIAVA ; CDR2 comprenant une séquence d'acides aminés SASYRYT; et CDR3 comprenant une séquence d'acides aminés QQHYITPLT.
  2. Anticorps humanisé, ou fragment de celui-ci, selon la revendication 1, comprenant les CRD de la murine RS7 Mab et la région du squelette (FR) des régions variables des chaînes légères et lourdes d'un anticorps humain, dans lequel les CRD de la région variable de la chaîne légère de RS7 MAb humanisé comprennent CDR1 comprenant une séquence d'acides aminés KASQDVSIAVA ; CDR2 comprenant une séquence d'acides aminés SASYRYT ; et CDR3 comprenant une séquence d'acides aminés QQHYITPLT ; et les CDR de la région variable de la chaîne lourde de RS7 MAb comprennent CDR1 comprenant une séquence d'acides aminés NYGMN ; CDR2 comprenant une séquence d'acides aminés WINTYTGEPTYTDDFKG et CDR3 comprenant une séquence d'acides aminés GGFGSSYWYFDV.
  3. Anticorps humanisé, ou un fragment de celui-ci, selon la revendication 2 comprenant en outre les FR des régions constantes des chaînes légère et lourde d'un anticorps humain.
  4. Anticorps humanisé ou un fragment de celui-ci selon l'une quelconque des revendications 1 ou 2, dans lequel les FR des régions variables des chaînes légère ou lourde dudit anticorps humanisé comprend au moins un acide aminé substitué par un résidu d'acide aminé se trouvant à une localisation correspondante dans la murine RS7 MAb.
  5. Anticorps humanisé ou un fragment de celui-ci selon la revendication 4, dans lequel au moins un des résidus d'acide aminé substitués est au niveau de la localisation choisie dans le groupe constitué par le résidu d'acide aminé 38, 46, 68 et 91 de la région variable de la chaîne lourde de la murine sur la figure 3B.
  6. Anticorps humanisé ou un fragment de celui-ci selon la revendication 4, dans lequel au moins un des résidus d'acide aminé substitués est au niveau de la localisation choisie dans le groupe constitué par le résidu d'acide aminé 20, 60, 85 et 100 de la région variable de la chaîne légère de la murine sur la figure 3A.
  7. Anticorps ou un fragment de celui-ci selon la revendication 1, dans lequel ledit anticorps ou fragment de celui-ci comprend une séquence de nucléotide VK de l'anticorps RS7 sur la figure 2A et la séquence de nucléotide VH de l'anticorps RS7 sur la figure 2B.
  8. Anticorps ou un fragment de celui-ci selon la revendication 1, dans lequel ledit anticorps ou fragment de celui-ci comprend une séquence de nucléotide VK de l'anticorps hRS7 sur la figure 4A.
  9. Conjugué diagnostique ou thérapeutique ciblant une cellule de cancer comprenant un composant d'anticorps comprenant un anticorps RS7 ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8, ou une protéine de fusion d'anticorps de celui-ci, qui se lie à ladite cellule, dans lequel ledit composant d'anticorps est lié à au moins un agent diagnostique ou à au moins un agent thérapeutique.
  10. Conjugué diagnostique selon la revendication 9, dans lequel ledit agent diagnostique comprend au moins un agent diagnostique photoactif.
  11. Conjugué diagnostique selon la revendication 9, dans lequel ledit agent diagnostique est un marqueur radioactif avec une énergie entre 25 et 4 000 KeV.
  12. Conjugué diagnostique selon la revendication 11, dans lequel ledit marqueur radioactif est un isotope à émission de rayon gamma, bêta ou de positron.
  13. Conjugué diagnostique selon la revendication 12, dans lequel ledit marqueur radioactif est choisi dans le groupe constitué par 125I, 131I, 123I, 124I, 86Y, 186Re, 188Re, 62Cu, 64Cu, 111In, 67Ga, 68Ga, 99mTc, 94mTc, 18F, 11C, 13N, 15O, 177Lu et 76Br.
  14. Conjugué diagnostique selon la revendication 9, dans lequel ledit agent diagnostique est un agent de contraste.
  15. Conjugué diagnostique selon la revendication 14, dans lequel ledit agent de contraste est un ion paramagnétique.
  16. Conjugué diagnostique selon la revendication 14, dans lequel ledit agent de contraste est un agent augmentant les ultrasons.
  17. Conjugué diagnostique selon la revendication 16, dans lequel ledit l'agent augmentant les ultrasons est un liposome qui comprend l'anticorps RS7 humanisé et un IgG ou un fragment de celui-ci.
  18. Conjugué diagnostique selon la revendication 17, dans lequel ledit liposome est rempli de gaz.
  19. Conjugué diagnostique selon la revendication 15, dans lequel ledit ion paramagnétique est un métal comprenant le manganèse, le fer ou le gadolinium.
  20. Conjugué thérapeutique selon la revendication 9, dans lequel ledit composant d'anticorps est une protéine de fusion d'anticorps comprenant un anticorps, ou un fragment de celui-ci, selon l'une quelconque des revendications 1 à 8, dans lequel au moins l'anticorps ou un fragment de celui-ci est lié à au moins un agent thérapeutique.
  21. Conjugué thérapeutique selon la revendication 9 ou 20, dans lequel ledit agent thérapeutique est choisi dans le groupe constitué par un marqueur radioactif, un immunomodulateur, une hormone, une enzyme, un agent thérapeutique photoactif, un agent cytotoxique, un agent oligonucléotide et une combinaison de ceux-ci.
  22. Conjugué thérapeutique selon la revendication 21, dans lequel ledit agent cytotoxique est un médicament ou une toxine.
  23. Conjugué thérapeutique selon la revendication 22, dans lequel ledit médicament possède la propriété pharmaceutique choisie dans le groupe constitué par des agents antimitotique, alkylant, antimétabolite, antiangiogénique, apoptotique, alcaloïde et antibiotique et des combinaisons de ceux-ci.
  24. Conjugué thérapeutique selon la revendication 22, dans lequel ledit médicament est choisi dans le groupe constitué par des moutardes d'azote, des dérivés éthylénimine, des sulfonates d'alkyle, des nitrosourées, des triazènes, des analogues de type acide folique, des anthracyclines, des taxanes, des inhibiteurs COX-2, des analogues de type pyrimidine, des analogues de type purine, des antibiotiques, des enzymes, des épipodophyllotoxines, des complexes de coordination du platine, des vinca-alcaloïdes, des urées substituées, des dérivés méthylhydrazine, des suppressants adrénocorticaux, des antagonistes, l'endostatine, des taxols, des camptothécines, des doxorubicines et leurs analogues, et une combinaison de ceux-ci.
  25. Conjugué thérapeutique selon la revendication 22, dans lequel ladite toxine est choisie dans le groupe constitué par la ricine, l'abrine, une alpha-toxine, la saporine, un ribonucléase (RNase), un DNase I, l'entérotoxine-A staphylococcique, une protéine antivirale de phytolaque, la gélonine, une diphthérine-toxine, la pseudomonas exotoxine, et la pseudomonas endotoxine.
  26. Conjugué thérapeutique selon la revendication 21, dans lequel ledit immunomodulateur est choisi dans le groupe constitué par une cytokine, un facteur de croissance de cellule souche, une lymphotoxine, un facteur hématopoïétique, un facteur stimulant une colonie (CSF), un interféron (IFN), un facteur de croissance de cellules souche, érythropoïétine, une thrombopoïétine et une combinaison de ceux-ci.
  27. Conjugué thérapeutique selon la revendication 26, dans lequel ladite lymphotoxine est un facteur de nécrose de tumeur (TNF), ledit facteur hématopoïétique est une interleukine (IL), ledit facteur stimulant une colonie est un facteur stimulant une colonie de granulocyte (G-CSF) ou un facteur stimulant une colonie de granulocyte macrophage (GM-CSF)), lesdits interférons sont des interférons -α, -β ou -γ et ledit facteur de croissance de cellule souche est désigné « facteur S1 ».
  28. Conjugué diagnostique selon la revendication 11, dans lequel ledit radionucléide a une énergie située entre 60 et 4 000 keV.
  29. Conjugué thérapeutique selon la revendication 26, dans lequel ledit immunomodulateur comprend IL-1, IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, IL-21, l'interféron y, le TNF-α ou une combinaison de ceux-ci.
  30. Conjugué thérapeutique selon la revendication 21, dans lequel ledit marqueur radioactif a une énergie située entre 60 et 700 keV.
  31. Conjugué thérapeutique selon la revendication 21, dans lequel ledit marqueur radioactif est choisi dans le groupe constitué par 32P, 33P, 47Sc, 64Cu, 67Cu, 67Ga, 86Y, 90Y, 111Ag, 111In, 125I, 131I, 142Pr, 153Sm, 161Tb, 166Dy, 166Ho, 177Lu, 186Re, 188Re, 189Re, 212Pb, 212Bi, 213Bi, 211At, 223Ra et 225Ac et des combinaisons de ceux-ci.
  32. Conjugué thérapeutique selon la revendication 21, dans lequel ledit agent thérapeutique photoactif est un chromogène ou un colorant.
  33. Anticorps multispécifique polyvalent comprenant un ou plusieurs sites de liaison d'antigène ayant une affinité envers la glycoprotéine-1 épithéliale et un ou plusieurs sites de liaison d'haptène ayant une affinité envers une molécule d'haptène, dans lequel ledit anticorps multispécifique polyvalent comprend un ou plusieurs anticorps selon l'une quelconque des revendications 1 à 8.
  34. Anticorps selon la revendication 33, comprenant en outre un agent diagnostique ou thérapeutique.
  35. Protéine de fusion d'anticorps comprenant au moins deux RS7 MAbs ou des fragments de ceux-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34.
  36. Protéine de fusion d'anticorps comprenant au moins un premier anticorps RS7 ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 et au moins un second MAb ou un fragment de celui-ci, autre que le MAb ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34.
  37. Protéine de fusion d'anticorps selon la revendication 36, dans laquelle ledit second MAb est un anticorps associé à un carcinome.
  38. Protéine de fusion d'anticorps selon la revendication 37, dans laquelle ledit anticorps associé à un carcinome se lie à un antigène sur un cancer choisi dans le groupe constitué par le cancer de la tête et du cou, du poumon, du sein, de l'ovaire, de l'estomac, de la prostate, du colon et/ou de la vessie.
  39. Protéine de fusion d'anticorps selon la revendication 37 dans lequel ledit anticorps associé à un carcinome est un anticorps ou un fragment réactif avec l'antigène choisi dans le groupe constitué par CEA, CSAp, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, AFP, HCG, HCG-beta, la ferritine, PAP, PLAP, EGP-2, l'histone, la cytokératine, la ténascine, CanAg, G250 du cancer du rein, VGFR1, VGFR2, VEGF, P1 GF, un facteur de croissance de type insuline, des produits oncogènes et une combinaison de ceux-ci.
  40. Séquence d'ADN comprenant un acide nucléique codant un MAb ou un fragment de celui-ci choisi dans le groupe constitué par :
    (a) un RS7 MAb ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 ;
    (b) une protéine de fusion d'anticorps selon la revendication 35 ;
    (c) une protéine de fusion d'anticorps comprenant au moins une premier RS7 MAb ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 et au moins un second MAb ou un fragment de celui-ci, autre que le MAb ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 ; et
    (d) une protéine de fusion d'anticorps selon c), dans laquelle ledit second MAb est un anticorps ou un fragment réactif avec l'antigène choisi l'antigène choisi dans le groupe constitué par CEA, CSAp, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, AFP, HCG, HCG-beta, la ferritine, PAP, PLAP, EGP-2, l'histone, la cytokératine, la ténascine, CanAg, G250 du cancer du rein, VGFR1, VGFR2, VEGF, P1GF, un facteur de croissance de type insuline, des produits oncogènes et une combinaison de ceux-ci.
  41. Vecteur d'expression comprenant la séquence d'ADN selon la revendication 40.
  42. Cellule hôte comprenant la séquence d'ADN selon la revendication 40.
  43. Utilisation d'une quantité thérapeutiquement efficace d'une protéine de fusion d'anticorps comprenant au moins deux Mab ou fragments de ceux-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 ou comprenant au moins un Mab ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 formulée dans un excipient pharmaceutiquement approprié dans la préparation d'un médicament destiné au traitement du cancer.
  44. Utilisation d'une quantité thérapeutiquement efficace d'un conjugué thérapeutique comprenant un RS7 Mab ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34 ou une protéine de fusion d'anticorps selon l'une quelconque des revendications 35 à 39, dans laquelle ledit Mab ou fragment de celui-ci ou protéine de fusion d'anticorps est lié à au moins un agent thérapeutique formulé dans un excipient pharmaceutiquement approprié dans la préparation d'un médicament destiné au traitement du cancer chez un patient.
  45. Utilisation selon la revendication 44, dans laquelle ledit agent thérapeutique est choisi dans le groupe constitué par une moutarde d'azote, un dérivé éthylénimine, un sulfonate d'alkyle, une nitrosourée, un triazène, un analogues de type acide folique, une anthracycline, un taxane, un inhibiteur COX-2, un analogue de type pyrimidine, un analogue de type purine, un antibiotique, une enzyme, une épipodophyllotoxine, un complexe de coordination du platine, un vinca-alcaloïde, une urée substituée, un dérivé méthylhydrazine, un suppressant adrénocortical, un antagoniste, l'endostatine, le taxol, des camptothécines, la doxorubicine, un analogue de doxorubicine, et une combinaison de ceux-ci.
  46. Utilisation selon la revendication 44, dans laquelle ledit agent thérapeutique est un médicament qui possède la propriété pharmaceutique choisie dans le groupe constitué par des agents antimitotique, alkylant, antimétabolite, antiangiogénique, apoptotique, alcaloïde, antibiotique et des combinaisons de ceux-ci.
  47. Utilisation selon la revendication 44, dans laquelle le conjugué comprend en outre un second Mab ou un fragment de celui-ci ou une protéine de fusion d'anticorps ou un fragment de celle-ci qui n'est pas selon l'une quelconque des revendications 1 à 8 et 33 à 39.
  48. Utilisation selon la revendication 47, dans laquelle ledit second Mab ou un fragment de celui-ci ou protéine de fusion d'anticorps ou un fragment de celle-ci est un Mab nu ou un fragment de celui-ci.
  49. Utilisation selon la revendication 47, dans laquelle ledit second Mab ou un fragment de celui-ci ou protéine de fusion d'anticorps ou un fragment de celle-ci est réactif avec l'antigène choisi dans le groupe constitué par CEA, AFP, HCG, CSAp, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, VEGF, P1GF, un facteur de croissance de type insuline, la ténascine, des produits oncogènes, la cytokératine et A33.
  50. Utilisation selon la revendication 49, dans laquelle ledit second Mab ou un fragment de celui-ci ou une protéine de fusion d'anticorps ou un fragment de celui-ci est conjuguée à un agent thérapeutique ou diagnostique.
  51. Utilisation selon la revendication 44, comprenant en outre un second Mab ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34.
  52. Utilisation selon la revendication 44, dans laquelle ledit anticorps RS7 ou un fragment de celui-ci ou protéine de fusion d'anticorps ou un fragment de celle-ci est destiné à une administration parentérale.
  53. Utilisation selon la revendication 52, dans laquelle ledit anticorps RS7 ou un fragment de celui-ci ou protéine de fusion d'anticorps ou un fragment de celle-ci est destiné à une administration dans un dosage de 10 à 2000 milligrammes de protéines par dose.
  54. Utilisation selon la revendication 53, dans laquelle ledit dosage est destiné à une administration répétée.
  55. Utilisation selon la revendication 54, dans laquelle les régions constante et charnière dudit anticorps RS7 comprennent les régions constante et charnière d'un IgG1 humain.
  56. Utilisation selon la revendication 47, dans laquelle ledit anticorps RS7 ou un fragment de celui-ci ou protéine de fusion d'anticorps ou un fragment de celle-ci est destiné à une administration avant, en conjonction, ou après qu'un second anticorps ou fragment de celui-ci soit administré audit patient.
  57. Utilisation selon la revendication 44, dans laquelle un premier site de liaison de l'anticorps RS7 ou d'un fragment de celui-ci est présent dans une protéine de fusion multispécifique polyvalente ou un conjugué chimique et un second site de liaison est réactif avec une substance de marqueur de tumeur autre qu'EGP-1.
  58. Utilisation selon la revendication 44, dans laquelle ledit anticorps RS7 ou un fragment de celui-ci ou protéine de fusion d'anticorps ou un fragment de celle-ci est destiné à une administration avant, en même temps ou après au moins un agent thérapeutique.
  59. Utilisation selon la revendication 57, dans laquelle ledit second anticorps ou fragment de celui-ci est conjugué à au moins un agent thérapeutique ou diagnostique.
  60. Conjugué thérapeutique comprenant un anticorps RS7 ou un fragment de celui-ci ou une protéine de fusion d'anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 39 destiné à une utilisation dans un procédé diagnostiquant la malignité chez un patient comprenant l'administration audit patient d'une quantité thérapeutiquement efficace dudit conjugué thérapeutique ou de ladite protéine de fusion d'anticorps, dans lequel ledit anticorps RS7 ou fragment de celui-ci ou protéine de fusion d'anticorps est lié à au moins un agent diagnostique formulé dans un excipient pharmaceutiquement approprié.
  61. Utilisation d'une quantité thérapeutiquement efficace d'une composition comprenant un anticorps RS7 ou un fragment de celui-ci ou une protéine de fusion d'anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 39 et un excipient pharmaceutiquement approprié dans la préparation d'un médicament destiné au traitement d'une cellule cancéreuse chez un patient.
  62. Utilisation selon la revendication 61, dans laquelle dans ladite composition l'anticorps RS7 est un anticorps nu et la composition comprend en outre un second anticorps nu ou un fragment de celui-ci qui n'est pas selon l'une quelconque des revendications 1 à 8 et 33 à 34
  63. Utilisation selon la revendication 62, dans laquelle ladite composition comprend en outre un second anticorps ou un fragment de celui-ci selon l'une quelconque des revendications 1 à 8 et 33 à 34
  64. Utilisation selon la revendication 62, dans laquelle ladite composition comprend en outre un second anticorps ou un fragment de celui-ci qui n'est pas selon l'une quelconque des revendications 1 à 8 et 33 à 34.
  65. Utilisation selon la revendication 63, dans laquelle ledit second anticorps ou un fragment de celui-ci est réactif avec l'antigène choisi dans le groupe constitué par CEA, AFP, HCQ, CSAp, Tn, Le(y), MUC-1-4, Tag-72, EGFR, HER2/neu, PSMA, PSA, VEGF, P1GF, un facteur de croissance de type insuline, la ténascine, des produits oncogènes, la cytokératine et A33.
  66. Utilisation selon la revendication 65, dans laquelle ledit second anticorps ou un fragment de celui-ci est réactif avec l'antigène choisi dans le groupe constitué par CEA, AFP, HCG, CSAp, Tn, Le(y), MUC-1-4, Tag-72, EGER, HER2/neu, PSMA, PSA, VEGF, P1GF, un facteur de croissance de type insuline, la ténascine, des produits oncogènes, la cytokératine et A33.
  67. Utilisation selon la revendication 62, dans laquelle ladite composition est destinée à une administration parentérale.
  68. Utilisation selon la revendication 67, dans laquelle ladite composition est destinée à une administration dans un dosage de 1 à 2000 milligrammes de protéines par dose.
  69. Utilisation selon la revendication 68, dans laquelle ledit dosage est destiné à une administration répétée.
  70. Utilisation selon la revendication 62, dans laquelle les régions constante et charnière dudit anticorps RS7 comprennent les régions constante et charnière d'un IgG1 humain.
  71. Utilisation selon la revendication 62, dans laquelle ladite composition est destinée à une administration avant, en conjonction, ou après un second anticorps nu ou fragment de celui-ci réactif avec un second marqueur de tumeur exprimé par ladite malignité.
  72. Utilisation selon la revendication 62, dans laquelle ledit anticorps RS7 est destiné à une administration avant, en même temps ou après un agent thérapeutique.
  73. Procédé de diagnostique d'une malignité chez un patient consistant à (i) réaliser une analyse de diagnostic in vitro sur un spécimen à partir dudit patient avec une composition comprenant un anticorps RS7 ou un fragment de celui-ci ou une protéine de fusion d'anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 39, dans lequel la protéine de fusion d'anticorps est une protéine de fusion d'anticorps nue.
  74. Procédé selon la revendication 73, dans lequel ladite malignité est un carcinome.
  75. Procédé selon la revendication 74, dans lequel ledit cancer est choisi dans le groupe constitué par le cancer de la tête et du cou, du poumon, de la prostate, de l'ovaire, du sein, du colon, de l'estomac et de la vessie.
  76. Procédé selon la revendication 73, dans lequel l'analyse de diagnostic in vitro est choisie dans le groupe constitué par des immuno-analyses, RT-PCR et l'immunohistochimie.
  77. Procédé selon la revendication 76, dans lequel l'analyse de diagnostic in vitro est RT-PCR ou des immuno-analyses.
  78. Procédé selon la revendication 73, dans lequel ledit spécimen est un fluide corporel ou un tissu.
  79. Procédé selon la revendication 77, dans lequel ladite analyse de diagnostic est l'immunohistochimie.
  80. Procédé selon la revendication 73, dans lequel ledit spécimen est une cellule ou un tissu.
  81. Utilisation d'un anticorps RS7 ou d'un fragment de celui-ci ou d'une protéine de fusion d'anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 39 dans la préparation d'un médicament destiné au traitement du cancer.
  82. Utilisation d'un conjugué thérapeutique comprenant un anticorps RS7 ou un fragment de celui-ci ou une protéine de fusion d'anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 39, dans laquelle ledit anticorps ou fragment de celui-ci ou protéine de fusion d'anticorps est lié à au moins un agent thérapeutique dans la préparation d'un médicament destiné au traitement du cancer.
  83. Utilisation d'un conjugué thérapeutique comprenant un anticorps RS7 ou un fragment de celui-ci ou une protéine de fusion d'anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 39, dans laquelle ledit anticorps ou fragment de celui-ci ou protéine de fusion d'anticorps est lié à au moins un agent thérapeutique dans la préparation d'un agent diagnostique destiné au diagnostic d'une malignité.
  84. Utilisation d'un agent diagnostique, d'un agent thérapeutique ou d'une combinaison de ceux-ci comprenant au moins un anticorps selon l'une quelconque des revendications 1 à 8 et 33 à 34 dans la préparation d'un agent destiné au ciblage d'une glycoprotéine-1 épithéliale sur une cellule.
  85. Utilisation selon la revendication 61, dans laquelle ledit anticorps est un anticorps nu.
EP03743420A 2002-03-01 2003-03-03 Anticorps rs7 Expired - Lifetime EP1483295B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP18211762.2A EP3483183B1 (fr) 2002-03-01 2003-03-03 Immunoconjugués comprenants des anticorps rs7 humanisés
EP08021299.6A EP2287201B1 (fr) 2002-03-01 2003-03-03 Anticorps RS7
CY20211100596T CY1124289T1 (el) 2002-03-01 2021-07-02 Ανοσοσυζευμα που περιλαμβανει εξανθρωποποιημενα αντισωματα rs7

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36022902P 2002-03-01 2002-03-01
US360229P 2002-03-01
PCT/GB2003/000885 WO2003074566A2 (fr) 2002-03-01 2003-03-03 Anticorps rs7

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP18211762.2A Division EP3483183B1 (fr) 2002-03-01 2003-03-03 Immunoconjugués comprenants des anticorps rs7 humanisés
EP08021299.6A Division EP2287201B1 (fr) 2002-03-01 2003-03-03 Anticorps RS7

Publications (2)

Publication Number Publication Date
EP1483295A2 EP1483295A2 (fr) 2004-12-08
EP1483295B1 true EP1483295B1 (fr) 2008-12-10

Family

ID=27788969

Family Applications (3)

Application Number Title Priority Date Filing Date
EP18211762.2A Expired - Lifetime EP3483183B1 (fr) 2002-03-01 2003-03-03 Immunoconjugués comprenants des anticorps rs7 humanisés
EP03743420A Expired - Lifetime EP1483295B1 (fr) 2002-03-01 2003-03-03 Anticorps rs7
EP08021299.6A Expired - Lifetime EP2287201B1 (fr) 2002-03-01 2003-03-03 Anticorps RS7

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18211762.2A Expired - Lifetime EP3483183B1 (fr) 2002-03-01 2003-03-03 Immunoconjugués comprenants des anticorps rs7 humanisés

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP08021299.6A Expired - Lifetime EP2287201B1 (fr) 2002-03-01 2003-03-03 Anticorps RS7

Country Status (18)

Country Link
US (10) US7238785B2 (fr)
EP (3) EP3483183B1 (fr)
JP (1) JP4354280B2 (fr)
KR (1) KR101002443B1 (fr)
CN (2) CN100360567C (fr)
AT (1) ATE417067T1 (fr)
AU (1) AU2003209447B8 (fr)
CA (1) CA2478047C (fr)
CY (1) CY1124289T1 (fr)
DE (1) DE60325184D1 (fr)
DK (1) DK3483183T3 (fr)
ES (1) ES2871905T3 (fr)
HU (1) HUE054986T2 (fr)
IL (1) IL163852A0 (fr)
PT (1) PT3483183T (fr)
SI (1) SI3483183T1 (fr)
TR (1) TR201901824T4 (fr)
WO (1) WO2003074566A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974263A (zh) * 2014-04-09 2015-10-14 广州复能基因有限公司 一种人重组乙型干扰素融合蛋白

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) * 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8435529B2 (en) 2002-06-14 2013-05-07 Immunomedics, Inc. Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
US8361464B2 (en) 2002-03-01 2013-01-29 Immunomedics, Inc. Anthracycline-Antibody Conjugates for Cancer Therapy
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US9745380B2 (en) * 2002-03-01 2017-08-29 Immunomedics, Inc. RS7 antibodies
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20040091937A1 (en) * 2002-06-05 2004-05-13 Claudio Dalvit Use of fluorine NMR for high throughput screening
US7597876B2 (en) * 2007-01-11 2009-10-06 Immunomedics, Inc. Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
US7993626B2 (en) * 2007-01-11 2011-08-09 Immunomedics, Inc. Methods and compositions for F-18 labeling of proteins, peptides and other molecules
JP4790413B2 (ja) * 2002-10-08 2011-10-12 イミューノメディクス、インコーポレイテッド 抗体療法
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
JP4959136B2 (ja) * 2002-12-13 2012-06-20 イミューノメディクス、インコーポレイテッド 細胞内で開裂可能な結合を有する免疫接合体
US20040202666A1 (en) * 2003-01-24 2004-10-14 Immunomedics, Inc. Anti-cancer anthracycline drug-antibody conjugates
CN1767860A (zh) * 2003-01-31 2006-05-03 免疫医疗公司 施用治疗和诊断剂的方法和组合物
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
CN2885311Y (zh) 2006-01-18 2007-04-04 郑成福 经尿道光动力疗法前列腺治疗仪
US10376711B2 (en) 2003-03-14 2019-08-13 Light Sciences Oncology Inc. Light generating guide wire for intravascular use
WO2005004809A2 (fr) * 2003-07-01 2005-01-20 Immunomedics, Inc. Porteuses polyvalentes d'anticorps bispecifiques
EP1663090A4 (fr) 2003-09-12 2010-07-21 Z Medica Corp Agent hemostatique de zeolite de calcium
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
JP2007508332A (ja) * 2003-10-17 2007-04-05 ノボ　ノルディスク　アクティーゼルスカブ 併用療法
US9481878B2 (en) 2004-02-13 2016-11-01 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
EP1720996A4 (fr) * 2004-02-13 2007-03-21 Immunomedics Inc Proteines de fusion contenant des rnases cytotoxiques recombinantes
US8551480B2 (en) * 2004-02-13 2013-10-08 Immunomedics, Inc. Compositions and methods of use of immunotoxins comprising ranpirnase (Rap) show potent cytotoxic activity
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
WO2006088912A2 (fr) 2005-02-15 2006-08-24 Virginia Commonwealth University Technologies minerales pour une hemostase aigue et pour le traitement de lesions aigues et d'ulceres chroniques
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US9326995B2 (en) 2005-04-04 2016-05-03 The Regents Of The University Of California Oxides for wound healing and body repair
NZ595386A (en) * 2005-08-11 2013-08-30 Arpi Matossian Rogers Peptides for treatment and diagnosis of autoimmune disease
AU2007209201A1 (en) * 2006-01-24 2007-08-02 Domantis Limited Fusion proteins that contain natural junctions
US20080131428A1 (en) * 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) * 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080305104A1 (en) * 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US8938898B2 (en) 2006-04-27 2015-01-27 Z-Medica, Llc Devices for the identification of medical products
US7604819B2 (en) 2006-05-26 2009-10-20 Z-Medica Corporation Clay-based hemostatic agents and devices for the delivery thereof
US20100008978A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Nanoparticles effective for internalization into cells
US20100009390A1 (en) * 2008-05-09 2010-01-14 The Regents Of The University Of California Mutant antibodies with high affinity for egfr
US7993640B2 (en) 2008-08-06 2011-08-09 Light Sciences Oncology, Inc. Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody
EP2337801A4 (fr) 2008-10-06 2012-07-25 Minerva Biotechnologies Corp Anticorps du muc1*
EP3517961B1 (fr) * 2009-01-09 2020-12-30 Oxford BioMedica (UK) Limited Facteurs
ES2611032T3 (es) 2009-02-05 2017-05-04 Oncoxx Biotech S.R.L. Anticuerpos monoclonales anti-Trop-2 y sus usos en el tratamiento y diagnóstico de tumores
LT3912643T (lt) 2009-02-13 2023-02-10 Immunomedics Inc. Imunokonjugatai su ląstelės viduje skaldoma jungtimi
PL2406284T3 (pl) 2009-03-10 2017-09-29 Biogen Ma Inc. Przeciwciała anty-bcma
US9296785B2 (en) 2009-04-17 2016-03-29 Wake Forest University Health Sciences IL-13 receptor binding peptides
CN102498177B (zh) * 2009-07-16 2014-12-24 贝克曼考尔特公司 新荧光染料及其用途
CN102596235A (zh) * 2009-08-31 2012-07-18 免疫医疗公司 显示有效细胞毒活性的包含豹蛙酶(rap)的免疫毒素的组合物和使用方法
CN102482701B (zh) 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
WO2011068845A1 (fr) * 2009-12-02 2011-06-09 Immunomedics, Inc. Combinaison de radioimmunotherapie et conjugues anticorps-medicament pour une meilleure therapie du cancer
US8663950B2 (en) 2010-01-11 2014-03-04 Arizona Board Of Regents Production of a monoclonal antibody therapeutic against west nile virus in plants
US8362207B2 (en) 2010-04-16 2013-01-29 Wake Forest University Health Sciences Multi-level specific targeting of cancer cells with IL-13
BR112012029281B1 (pt) * 2010-05-17 2020-12-08 Livtech, Inc anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
EP2594589A1 (fr) * 2010-06-10 2013-05-22 Sapporo Medical University ANTICORPS ANTI-Trop-2
KR20130108305A (ko) * 2010-08-23 2013-10-02 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US8858969B2 (en) 2010-09-22 2014-10-14 Z-Medica, Llc Hemostatic compositions, devices, and methods
SG193564A1 (en) * 2011-03-25 2013-10-30 Genentech Inc Novel protein purification methods
CA2831572C (fr) 2011-05-02 2019-11-26 Immunomedics, Inc. Concentration d'ultrafiltration d'anticorps a allotype selectionne pour une administration de petit volume
WO2013006244A1 (fr) * 2011-06-08 2013-01-10 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Agents thérapeutiques de type anticorps monoclonaux bispécifiques contre le virus du nil occidental dotés d'une pénétration améliorée dans le snc
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence ANTIRICIN ANTIBODIES AND APPLICATIONS THEREOF
EP2776470A2 (fr) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Anticorps spécifiques de trop-2 et leurs utilisations
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
KR102189877B1 (ko) 2012-06-22 2020-12-14 지-메디카 엘엘씨 지혈 장치
US9382329B2 (en) 2012-08-14 2016-07-05 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to Trop-2 expressing cells
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN104379169A (zh) 2012-08-14 2015-02-25 Ibc药品公司 用于治疗疾病的t-细胞重定向双特异性抗体
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN108517014A (zh) 2012-08-21 2018-09-11 詹森药业有限公司 利培酮半抗原的抗体及其用途
CN104736567B (zh) 2012-08-21 2019-09-03 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
EP2888234B1 (fr) 2012-08-21 2017-12-06 Janssen Pharmaceutica NV Haptènes d'aripiprazole et leur utilisation dans des dosages immunologiques
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
WO2015012904A2 (fr) 2012-12-13 2015-01-29 Immunomedics, Inc. Immunoconjugués anticorps-sn-38 avec un lieur cl2a
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
SI2900277T1 (sl) 2012-12-13 2022-05-31 Immunomedics, Inc. Odmerki imunokonjugatov protiteles in SN-38 za boljšo učinkovitost in zmanjšano toksičnost
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
WO2014124227A1 (fr) 2013-02-07 2014-08-14 Immunomedics, Inc. Forme de pro-médicament (p2pdox) de la 2-pyrrolinodoxorubicine fortement puissante conjuguée à des anticorps pour la thérapie ciblée du cancer
EP2774930A1 (fr) 2013-03-07 2014-09-10 Aptenia S.R.L. Composés de métallocène et molécules marquées comprenant ceux-ci pour l'imagerie in vivo
PL2970492T3 (pl) 2013-03-15 2019-10-31 Univ Wake Forest Health Sciences Przeciwciała przeciwko ludzkim i psim il-13ra2
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
CA2920192A1 (fr) * 2013-09-27 2015-04-02 Immunomedics, Inc. Conjugues anticorps anti-trop-2-medicament et leurs utilisations
DE202014011600U1 (de) 2013-10-18 2023-05-31 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Markierte Inhibitoren des prostataspezifischen Membranantigens (PSMA), deren Verwendung als bildgebende Mittel und pharmazeutische Wirkstoffe für die Behandlung von Prostatakrebs
PL3068797T3 (pl) 2013-11-11 2020-06-29 Wake Forest University Health Sciences Konstrukty wielowalentnego celowania w nowotwory
SG11201605215YA (en) * 2013-12-25 2016-08-30 Daiichi Sankyo Co Ltd Anti-trop2 antibody-drug conjugate
WO2015113055A2 (fr) 2014-01-27 2015-07-30 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Anticorps dérivés de végétaux et dérivés qui réduisent le risque de facilitation de l'infection dépendante des anticorps
ES2978993T3 (es) 2014-02-21 2024-09-23 Ibc Pharmaceuticals Inc Terapia de enfermedades mediante la inducción de la respuesta inmunitaria a las células que expresan Trop-2
EP3110445A4 (fr) 2014-02-25 2017-09-27 Immunomedics, Inc. Anticorps rfb4 humanisés anti-cd22
KR20230155600A (ko) 2014-04-03 2023-11-10 아이쥐엠 바이오사이언스 인코포레이티드 변형된 j-사슬
US9580495B2 (en) 2014-06-24 2017-02-28 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN107073135B (zh) 2014-09-08 2023-06-06 鲁塔纳有限公司 用于将分子递送至细胞的细胞质中的构建体
EP3204018B1 (fr) 2014-10-07 2021-08-25 Immunomedics, Inc. Utilisation néoadjuvante de conjugués anticorps-médicaments
US10501555B2 (en) 2014-12-04 2019-12-10 Abruzzo Theranostic S.R.L. Humanized anti-trop-2 monoclonal antibodies and uses thereof
EP3256494A4 (fr) 2015-02-10 2018-12-05 Minerva Biotechnologies Corporation Anticorps anti-muc1* humanisés
CN107995863A (zh) 2015-04-20 2018-05-04 特雷罗药物股份有限公司 通过线粒体分析预测对阿伏西地的应答
CN107428837A (zh) 2015-04-22 2017-12-01 免疫医疗公司 循环trop‑2阳性癌细胞的分离、检测、诊断和/或鉴定
AU2016264212B2 (en) 2015-05-18 2020-10-22 Sumitomo Pharma Oncology, Inc. Alvocidib prodrugs having increased bioavailability
WO2016201300A1 (fr) * 2015-06-12 2016-12-15 Immunomedics, Inc. Traitement de maladies avec des constructions de récepteur d'antigène chimérique (car) et lymphocytes t (car-t) ou cellules nk (car-nk) exprimant des constructions car
JP6980980B2 (ja) 2015-06-25 2021-12-15 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN116059395A (zh) 2015-06-29 2023-05-05 第一三共株式会社 用于选择性制造抗体-药物缀合物的方法
EP3316885B1 (fr) 2015-07-01 2021-06-23 Immunomedics, Inc. Immunoconjugués d'anticorps sn-38 avec un lieur cl2a
WO2017024073A1 (fr) 2015-08-03 2017-02-09 Tolero Pharmaceuticals, Inc. Thérapies combinatoires pour le traitement du cancer
AU2016329197B2 (en) 2015-09-30 2021-01-21 Igm Biosciences, Inc. Binding molecules with modified J-chain
WO2017059387A1 (fr) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Molécules de liaison à chaîne j modifiée
MY196809A (en) * 2015-12-24 2023-05-03 Kyowa Kirin Co Ltd (),()-unsaturated amide compound
WO2017139623A1 (fr) 2016-02-10 2017-08-17 Immunomedics, Inc. La combinaison inhibiteurs abcg2-sacituzumab govitécan (immu-132) surmonte la résistance à sn-38 dans les cancers exprimant trop-2
JP7379795B2 (ja) 2016-04-27 2023-11-15 イミューノメディクス、インコーポレイテッド チェックポイント阻害薬に再発／耐性を示す腫瘍を治療するための抗Ｔｒｏｐ－２－ＳＮ－３８抗体薬物複合体の効果
IL263616B1 (en) 2016-07-07 2024-09-01 Univ Leland Stanford Junior Antibody-adjuvant conjugates
WO2018036438A1 (fr) * 2016-08-23 2018-03-01 四川科伦博泰生物医药股份有限公司 Conjugué anticorps-médicament et son procédé de préparation et d'application
JP6786973B2 (ja) * 2016-09-08 2020-11-18 ブラザー工業株式会社 画像解析装置
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
WO2018094275A1 (fr) 2016-11-18 2018-05-24 Tolero Pharmaceuticals, Inc. Promédicaments de l'alvocidib et leur utilisation en tant qu'inhibiteurs de protéines kinases
TW201828993A (zh) 2016-12-12 2018-08-16 日商第一三共股份有限公司 抗體－藥物結合物與免疫檢查點抑制劑之組合
WO2018119000A1 (fr) 2016-12-19 2018-06-28 Tolero Pharmaceuticals, Inc. Peptides de profilage et procédés de profilage de sensibilité
BR112019012847A2 (pt) 2017-01-17 2019-12-10 Daiichi Sankyo Co Ltd anticorpo ou fragmento funcional do anticorpo, polinucleotídeo, vetor de expressão, células hospedeiras, método para produção de um anticorpo de interesse ou de um fragmento funcional do anticorpo e para produção de um conjugado de anticorpo-fármaco, conjugado de anticorpo-fármaco, composição farmacêutica, fármaco antitumoral, e, método de tratamento de um tumor.
EP3585424A4 (fr) * 2017-02-27 2021-01-13 Dragonfly Therapeutics, Inc. Protéines de liaison multi-spécifiques ciblant caix, ano1, la mésothéline, trop2, cea ou la claudine-18.2
US10918734B2 (en) 2017-03-27 2021-02-16 Immunomedics, Inc. Treatment of high Trop-2 expressing triple negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51
WO2018187074A1 (fr) 2017-04-03 2018-10-11 Immunomedics, Inc. Administration par voie sous-cutanée de conjugués anticorps-médicament à titre de thérapie anticancéreuse
CN110312730B (zh) 2017-04-19 2024-06-18 四川科伦博泰生物医药股份有限公司 细胞毒素和偶联物、其用途和制备方法
CN107446050A (zh) * 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
KR102422860B1 (ko) 2017-08-31 2022-07-19 다이이찌 산쿄 가부시키가이샤 항체-약물 콘주게이트의 신규 제조 방법
JP7366745B2 (ja) 2017-08-31 2023-10-23 第一三共株式会社 抗体－薬物コンジュゲートの改良製造方法
WO2019055579A1 (fr) 2017-09-12 2019-03-21 Tolero Pharmaceuticals, Inc. Régime de traitement pour des cancers qui sont insensibles aux inhibiteurs de bcl-2 à l'aide de l'inhibiteur de mcl-1 alvocidib
IL301637B2 (en) 2017-09-29 2024-10-01 Daiichi Sankyo Co Ltd Conjugation of an antibody with a pyrrolobenzodiazepine derivative
CA3080236A1 (fr) 2017-12-15 2019-06-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Conjugue de molecule bioactif, son procede de preparation et son utilisation
CN108680750A (zh) * 2017-12-29 2018-10-19 广西壮族自治区人民医院 Trop2蛋白表达量的elisa检测方法及试剂盒
TW201945026A (zh) * 2018-01-29 2019-12-01 美商希拉諾斯醫療公司 結合erfe之抗體及使用方法
TWI825098B (zh) 2018-05-18 2023-12-11 德商葛萊高托普公司 抗ｍｕｃ１抗體
US20210340628A1 (en) 2018-08-23 2021-11-04 Daiichi Sankyo Company, Limited Sensitivity marker for antibody-drug conjugate
EP3856257A1 (fr) 2018-09-26 2021-08-04 Ascendis Pharma A/S Hydrogels dégradables d'acide hyaluronique
WO2020094670A1 (fr) 2018-11-05 2020-05-14 Synaffix B.V. Anticorps-conjugués pour le ciblage de tumeurs exprimant trop -2
EP3890749A4 (fr) 2018-12-04 2022-08-03 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de cdk9 et leurs polymorphes destinés à être utilisés en tant qu'agents pour le traitement du cancer
US20220089768A1 (en) * 2019-01-04 2022-03-24 Trio Pharmaceuticals, Inc. Multi-specific protein molecules and uses thereof
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2
WO2020191326A1 (fr) 2019-03-20 2020-09-24 Sumitomo Dainippon Pharma Oncology, Inc. Traitement de la leucémie myéloïde aiguë (aml) après échec du vénétoclax
WO2020196474A1 (fr) 2019-03-25 2020-10-01 第一三共株式会社 Conjugué anticorps-dérivé de pyrrolobenzodiazépine
TWI841715B (zh) 2019-03-27 2024-05-11 日商第一三共股份有限公司 抗體-吡咯并苯二氮呯衍生物結合物及ｐａｒｐ抑制劑之組合及其用途
JP2022534725A (ja) 2019-05-29 2022-08-03 第一三共株式会社 抗体薬物複合体の用量
KR20220107223A (ko) 2019-11-27 2022-08-02 알렉소 온콜로지 인크. 암 치료를 위한 병용 요법
MX2022008474A (es) 2020-01-22 2022-08-02 Jiangsu Hengrui Medicine Co Conjugado de anticuerpo anti-trop-2-analogo de exatecan y uso medico del mismo.
KR20220130160A (ko) 2020-01-22 2022-09-26 상하이 센후이 메디슨 컴퍼니 리미티드 에리불린 유도체의 약물 접합체, 이를 제조하기 위한 방법 및 의료분야에서 이의 용도
WO2021188896A1 (fr) 2020-03-20 2021-09-23 Immunomedics, Inc. Biomarqueurs pour une thérapie par sacituzumab govitécan
CN116963782A (zh) 2020-05-03 2023-10-27 联宁（苏州）生物制药有限公司 包含抗trop-2抗体的抗体药物偶联物
CA3176626A1 (fr) 2020-05-08 2021-11-11 David Dornan Substrat pour elastase, immunoconjugues de liaison peptidique et leurs utilisations
CN116390772A (zh) 2020-07-07 2023-07-04 博泰康医药公司 新型美登素类似物作为adc有效载荷及其在癌症治疗中的用途
JP2023533173A (ja) 2020-07-09 2023-08-02 エフ． ホフマン－ラ ロシュ アーゲー タンパク質の濃縮組成物、それらの調製及びそれらの使用
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
US20240092931A1 (en) * 2020-08-24 2024-03-21 Janux Therapeutics, Inc. Antibodies targeting trop2 and cd3 and uses thereof
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
IT202000031838A1 (it) 2020-12-22 2022-06-22 Saverio Alberti Piattaforma per ottenere anticorpi monoclonali diretti contro antigeni processati tumore-specifici
AU2021423664A1 (en) 2021-01-28 2023-09-07 Genequantum Healthcare (Suzhou) Co., Ltd. Ligase fusion proteins and applications thereof
CA3212926A1 (fr) 2021-03-26 2022-09-29 Gary Brandt Immunoconjugues de 2-amino-4-carboxamide-benzazepine et leurs utilisations
CN117940168A (zh) 2021-03-26 2024-04-26 博尔特生物治疗药物有限公司 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
EP4331612A1 (fr) 2021-04-29 2024-03-06 Hyslink Therapeutics Procédé de préparation et application d'un médicament conjugué à un anticorps
WO2022239720A1 (fr) 2021-05-10 2022-11-17 公益財団法人川崎市産業振興財団 Anticorps d'affinité de liaison vis-à-vis d'antigènes réduite
BR112023022774A2 (pt) 2021-05-13 2024-01-02 Alx Oncology Inc Terapias de combinação para tratamento de câncer
TW202313094A (zh) 2021-05-18 2023-04-01 美商基利科學股份有限公司 使用ＦＬＴ３Ｌ—Ｆｃ融合蛋白之方法
US20240269315A1 (en) 2021-06-02 2024-08-15 Bio-Thera Solutions, Ltd. Drug conjugate and use thereof
KR20240019330A (ko) 2021-06-11 2024-02-14 길리애드 사이언시즈, 인코포레이티드 Mcl-1 저해제와 항체 약물 접합체의 조합
WO2022261301A1 (fr) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Inhibiteurs de mcl-1 en combinaison avec des agents anticancéreux
US20240279334A1 (en) 2021-06-17 2024-08-22 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
MX2024000895A (es) 2021-07-21 2024-02-06 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica que contiene el conjugado del farmaco anticuerpo anti-trop2 y su aplicacion.
JP2024534257A (ja) 2021-08-12 2024-09-18 上海才致薬成生物科技有限公司 二重特異性組換えタンパク質及びその使用
EP4385522A1 (fr) 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Conjugué anticorps-médicament à base d'inhibiteur de microtubules
CN117881431A (zh) 2021-08-24 2024-04-12 昆山新蕴达生物科技有限公司 一种由可断裂连接子偶联的抗体偶联药物
CN118139858A (zh) 2021-10-28 2024-06-04 吉利德科学公司 吡地嗪-3(2h)-酮衍生物
KR20240097895A (ko) 2021-10-29 2024-06-27 길리애드 사이언시즈, 인코포레이티드 Cd73 화합물
WO2023076599A1 (fr) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Immunoconjugués agonistes de tlr avec des anticorps mutants de cystéine, et leurs utilisations
CN116199784A (zh) * 2021-11-30 2023-06-02 泽达生物医药有限公司 抗trop-2/pd-l1双特异性抗体
EP4442828A1 (fr) 2021-11-30 2024-10-09 Daiichi Sankyo Company, Limited Anticorps masqués clivables par protéase
WO2023103854A1 (fr) 2021-12-09 2023-06-15 昆山新蕴达生物科技有限公司 Conjugué anticorps-médicament présentant une affinité améliorée, son procédé de préparation et son application
CA3237577A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de degradation des doigts de zinc de la famille ikaros et leurs utilisations
CA3239528A1 (fr) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Agents de degradation de doigt de zinc de la famille ikaros et utilisations associees
CN118401259A (zh) 2022-01-13 2024-07-26 四川科伦博泰生物医药股份有限公司 抗trop-2抗体偶联药物和其他治疗剂的组合用途
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
CN118647408A (zh) 2022-02-16 2024-09-13 苏州宜联生物医药有限公司 抗体-艾日布林或其衍生物的偶联物、其中间体、制备方法、药物组合物和用途
WO2023164640A1 (fr) * 2022-02-24 2023-08-31 Xencor, Inc. Anticorps anti-cd28 x anti-trop2
AU2023233730A1 (en) 2022-03-17 2024-09-26 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023180485A1 (fr) 2022-03-23 2023-09-28 Synaffix B.V. Anticorps-conjugués pour le ciblage de tumeurs exprimant trop-2
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2023201267A1 (fr) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant trop-2
WO2023201268A1 (fr) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Polythérapie pour le traitement de cancers exprimant un antigène tumoral
WO2023205719A1 (fr) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Composés modulateurs de kras g12d
WO2023240135A2 (fr) 2022-06-07 2023-12-14 Actinium Pharmaceuticals, Inc. Chélateurs et conjugués bifonctionnels
US20240116928A1 (en) 2022-07-01 2024-04-11 Gilead Sciences, Inc. Cd73 compounds
WO2024097812A1 (fr) 2022-11-04 2024-05-10 Gilead Sciences, Inc. Thérapie pour le traitement du cancer de la vessie
WO2024137852A1 (fr) 2022-12-22 2024-06-27 Gilead Sciences, Inc. Inhibiteurs de prmt5 et leurs utilisations
WO2024138128A2 (fr) 2022-12-23 2024-06-27 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
WO2024173387A1 (fr) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Immunoconjugués d'aza-benzazépine et leurs utilisations
WO2024186626A1 (fr) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Immunoconjugués d'agonistes de sting aza-bicycliques et leurs utilisations

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4624846A (en) 1983-07-29 1986-11-25 Immunomedics, Inc. Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
FR2604092B1 (fr) 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5185254A (en) * 1988-12-29 1993-02-09 The Wistar Institute Gene family of tumor-associated antigens
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
SG41929A1 (en) 1992-09-25 1997-08-15 Commw Scient Ind Res Org Target binding polypeptide
CA2150262C (fr) 1992-12-04 2008-07-08 Kaspar-Philipp Holliger Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
US6180377B1 (en) * 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
GB9316989D0 (en) * 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5443953A (en) 1993-12-08 1995-08-22 Immunomedics, Inc. Preparation and use of immunoconjugates
WO1996004925A1 (fr) 1994-08-12 1996-02-22 Immunomedics, Inc. Immunoconjugues et anticorps de type humain specifiques contre des lymphomes malins a cellules b et des cellules leucemiques
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
IL123294A0 (en) 1995-10-19 1998-09-24 Bristol Myers Squibb Co Monoclonal antibody BR110 and uses thereof
CA2249320C (fr) 1996-03-20 2008-12-23 Immunomedics, Inc. Anticorps humanises glycosyles specifiques des lymphocytes b
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US6558669B1 (en) * 1996-08-28 2003-05-06 Immunomedics, Inc. Stable radioiodine conjugates and methods for their synthesis
AU4373197A (en) 1996-09-19 1998-04-14 Diagnocure Inc. Recombinant single chain antibodies directed against the gp54 cancer marker, composition comprising same and use thereof
US6653104B2 (en) * 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP4113670B2 (ja) * 1998-06-22 2008-07-09 イムノメディクス， インコーポレイテッド プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
EP1157041B1 (fr) * 1999-03-01 2005-06-01 Genentech, Inc. Anticorps destines au traitement et au diagnostic du cancer
GB9911569D0 (en) * 1999-05-18 1999-07-21 Oxford Biomedica Ltd Antibodies
US6824780B1 (en) 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
DE10034607A1 (de) * 2000-07-20 2002-02-07 Gundram Jung Multispezifisches Reagenz zur selektiven Stimulierung von Zelloberflächenrezeptoren
WO2003057829A2 (fr) * 2001-12-26 2003-07-17 Immunomedics, Inc. Procede de production d'agents polyvalents plurispecifiques a partir des domaines vh et vl
US9770517B2 (en) * 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20080305104A1 (en) 2006-02-24 2008-12-11 Young David S F Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
US20080213267A1 (en) 2006-02-24 2008-09-04 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
ES2611032T3 (es) 2009-02-05 2017-05-04 Oncoxx Biotech S.R.L. Anticuerpos monoclonales anti-Trop-2 y sus usos en el tratamiento y diagnóstico de tumores
BR112012029281B1 (pt) 2010-05-17 2020-12-08 Livtech, Inc anticorpo contra trop-2 humano, anticorpo monoclonal contra trop-2 humano, fragmento de anticorpo derivado de anticorpo, hibridoma, conjugado, composição farmacêutica, uso de composição farmacêutica, método para detectar um tumor e kit para tratar, diagnosticar ou detectar um tumor
EP2594589A1 (fr) 2010-06-10 2013-05-22 Sapporo Medical University ANTICORPS ANTI-Trop-2
WO2012131527A1 (fr) 2011-04-01 2012-10-04 Wyeth Llc Conjugués anticorps-médicament
EP2776470A2 (fr) 2011-11-11 2014-09-17 Rinat Neuroscience Corporation Anticorps spécifiques de trop-2 et leurs utilisations
US9427464B2 (en) 2011-11-22 2016-08-30 Chiome Bioscience Inc. Anti-human TROP-2 antibody having an antitumor activity in vivo
KR102188537B1 (ko) 2019-08-14 2020-12-08 라인플러스 주식회사 유니캐스트 및 멀티캐스트를 이용한 그룹 통화 방법 및 시스템

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104974263A (zh) * 2014-04-09 2015-10-14 广州复能基因有限公司 一种人重组乙型干扰素融合蛋白

Also Published As

Publication number Publication date
EP1483295A2 (fr) 2004-12-08
KR20040089694A (ko) 2004-10-21
US20140120035A1 (en) 2014-05-01
EP2287201A2 (fr) 2011-02-23
US20120141372A1 (en) 2012-06-07
IL163852A0 (en) 2005-12-18
SI3483183T1 (sl) 2021-08-31
AU2003209447B2 (en) 2008-09-18
US9999668B2 (en) 2018-06-19
CY1124289T1 (el) 2022-07-22
TR201901824T4 (tr) 2019-03-21
US20180133322A1 (en) 2018-05-17
ATE417067T1 (de) 2008-12-15
EP2287201A3 (fr) 2012-04-04
CA2478047C (fr) 2014-01-21
JP2006502698A (ja) 2006-01-26
WO2003074566A3 (fr) 2004-03-04
US9833511B2 (en) 2017-12-05
US20170274079A1 (en) 2017-09-28
DE60325184D1 (de) 2009-01-22
US8758752B2 (en) 2014-06-24
CA2478047A1 (fr) 2003-09-12
PT3483183T (pt) 2021-06-02
US20070212350A1 (en) 2007-09-13
US20180250406A1 (en) 2018-09-06
ES2871905T3 (es) 2021-11-02
US10179171B2 (en) 2019-01-15
DK3483183T3 (da) 2021-06-21
US20040001825A1 (en) 2004-01-01
US8084583B2 (en) 2011-12-27
US7238785B2 (en) 2007-07-03
EP2287201B1 (fr) 2018-12-12
CN101264325B (zh) 2017-03-01
CN101264325A (zh) 2008-09-17
US20140286861A1 (en) 2014-09-25
WO2003074566A2 (fr) 2003-09-12
KR101002443B1 (ko) 2010-12-17
US20190083621A1 (en) 2019-03-21
AU2003209447B8 (en) 2008-10-23
JP4354280B2 (ja) 2009-10-28
US8574575B2 (en) 2013-11-05
US20100221177A1 (en) 2010-09-02
EP3483183A1 (fr) 2019-05-15
CN1649903A (zh) 2005-08-03
HUE054986T2 (hu) 2021-10-28
EP3483183B1 (fr) 2021-04-21
AU2003209447A1 (en) 2003-09-16
US7517964B2 (en) 2009-04-14
CN100360567C (zh) 2008-01-09
US9849176B2 (en) 2017-12-26

Similar Documents

Publication Publication Date Title
US10179171B2 (en) RS7 antibodies
US9745380B2 (en) RS7 antibodies
EP2216342B1 (fr) Anticorps anti-CD19
US7772373B2 (en) Internalizing anti-CD74 antibodies and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040930

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: QU, ZHENGXING

Inventor name: GOVINDAN, SERENGULAM

Inventor name: GOLDENBERG, DAVID, M.

Inventor name: HANSEN, HANS, J.

17Q First examination report despatched

Effective date: 20041122

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60325184

Country of ref document: DE

Date of ref document: 20090122

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: ISLER & PEDRAZZINI AG

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090321

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090310

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090511

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090331

26N No opposition filed

Effective date: 20090911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090311

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20090611

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20081210

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20220110

Year of fee payment: 20

Ref country code: GB

Payment date: 20220113

Year of fee payment: 20

Ref country code: DE

Payment date: 20220105

Year of fee payment: 20

Ref country code: CH

Payment date: 20220114

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20220110

Year of fee payment: 20

Ref country code: NL

Payment date: 20220118

Year of fee payment: 20

Ref country code: IT

Payment date: 20220210

Year of fee payment: 20

Ref country code: FR

Payment date: 20220118

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60325184

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20230302

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20230302

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230303

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20230302

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230518

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230527